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ABSTRACT 
In this Ph.D. project the possibility of grafting melanocortin receptor binding sequences 
into the inhibitor cystine knotted peptide gurmarin was investigated. The goal of designing 
these analogues was to produce highly stable peptide agonists with potential for obesity 
treatment  
 
Inhibitor cystine knotted peptides are a group of peptides found in a variety of plant and 
animal species. They all contain six cysteines forming three disulphides which determine 
their tertiary structure and provide them with exceptional proteolytic stability. It has been 
demonstrated that these peptides can be used as molecular scaffolds into which peptide 
sequences of pharmaceutical interest can be incorporated, thus providing highly stable drug 
candidates.  
The melanocortin receptors are a family of five G protein-coupled receptors 
distributed throughout the body. The melanocortin 4 receptor is found in the brain where 
it regulates appetite and energy expenditure. The melanocortin receptors are activated by 
peptides containing a His-Phe-Arg-Trp tetrapeptide sequence. Consequently, inhibitor 
cystine knotted peptides in which this tetrapeptide are grafted could provide novel appetite 
regulating peptides for the treatment of obesity. 
 
First, a stable method to synthesise gurmarin was developed. The peptide was oxidised by a 
random oxidation method using a buffer containing a glutathione/cystamine redox pair. 
Various attempts were made to confirm the disulphide connectivity of the randomly 
oxidised gurmarin. The native disulphide connectivity of the randomly oxidised gurmarin 
was ultimately confirmed by a synthetic approach. This approach used a combination of 
thermolysin cleavage of the randomly oxidised peptide and the development of an 
orthogonal oxidation method. In this method, the disulphides in gurmarin were oxidised 
sequentially using three different pairs of cysteine side chain protection groups, which 
allowed selective disulphide formation. 
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 Secondly, the redox buffer oxidation was used to synthesise six melanocortin 
analogues of gurmarin. These peptides were designed based on a structural alignment of 
gurmarin and agouti-related protein, an endogenous antagonist of the melanocortin 
receptors. The C-terminal part of agouti-related protein contains multiple disulphides 
similar to the inhibitor cystine knot of gurmarin. In addition, two tetra-disulphide 
analogues of gurmarin was designed and synthesised based on the alignment with agouti-
related protein. The melanocortin analogues were characterised for their binding to the 
melanocortin receptors. In general, it was proved that it is possible to synthesise gurmarin 
analogues which bind to the melanocortin receptors. The analogue with highest affinity to 
the melanocortin 4 receptor had a binding affinity of 500 nM which is around ten-fold 
lower affinity than the endogenous agonist α-melanocyte stimulating hormone.  
 Finally, it was demonstrated that it was possible to synthesise melanocortin 
analogues of the cyclic cystine knotted peptide kalata B1, a plant peptide which two termini 
are cyclised. These analogues were shown by NMR spectroscopy to adopt similar three-
dimensional folds as kalata B1. One analogue was found to bind to the melanocortin 4 
receptor with a binding affinity of 29 nM, which is higher affinity than α-melanocortin 
stimulating hormone. However, the analogue was less potent than α-melanocortin 
stimulating hormone at activating the melanocortin 4 receptor. In addition, the analogues 
were shown to be highly resistant to proteolysis compared to α-melanocyte stimulating 
hormone. 
 
In summary, the possibility of grafting melanocortin binding sequences into cystine 
knotted peptides was confirmed using two different peptides as molecular scaffolds. The 
ability of these melanocortin analogues to adopt native folds was confirmed. In addition, it 
was demonstrated that the synthesised peptides in fact are able to bind to and activate the 
melanocortin 4 receptor. Moreover, the peptides were resistant to proteolysis. This novel 
melanocortin grafting approach provides new candidates for the development of drugs 
treating obesity. 
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RESUMÉ 
I dette Pd.D.-projekt blev muligheden for at grafte melanocortin receptor bindende 
sekvenser i det inhibitor cystine knottede peptid gurmarin undersøgt. Målet med at designe 
disse analoger var, at producere stabile peptid agonister med potentiale for at behandle 
fedme. 
 
Inhibitor cystine knottede peptider er en gruppe af peptider, som findes i forskellige plante- 
og dyrearter. De indeholder alle seks cysteiner, som danner tre disulfider, der bestemmer 
deres tertiære struktur og giver dem ekseptionel proteolytisk stabilitet. Det er blevet vist, at 
disse peptider kan blive brugt som molekylære platformer, i hvilke peptidsekvenser af 
farmaceutisk interesse kan blive indsat, hvormed meget stabile lægemidler kan blive 
fremstillet. 
 Melanocortinreceptorerne er en familie af fem G-protein-koblede receptorer, 
der findes over hele kroppen. Melanocortin 4 receptoren findes i hjernen, hvor den 
regulerer appetit og energiomsætning. Melanocortinreceptorerne bliver aktiveret af 
peptider, der indeholder en His-Phe-Arg-Trp tetrapeptidsekvens. Dermed kan inhibitor 
cystine knottede peptider, der har denne sekvens graftet måske blive til nye 
appetitregulerende peptider til behandling af fedme. 
  
Først blev en stabil metode til at syntetisere gurmarin udviklet. Peptidet blev oxideret med 
en oxidationsmetode, der vilkårligt danner disulfiderne ved brug af en buffer indeholdende 
et glutathion/cystamin redox-par. Forskellige forsøg på at bekræfte disulfid-kombinationen 
i det vilkårligt oxiderede gurmarin blev afprøvet. Den native disulfid-kombination af det 
vilkårligt oxiderede gurmarin blev til sidst bekræftet med en syntetisk metode. Denne 
metode brugte en kombination af thermolysin-kløvning af det vilkårligt oxiderede peptid 
og udviklingen af en orthogonal oxidationsmetode. I denne metode blev disulfiderne i 
gurmarin oxideret i rækkefølge, ved at bruge tre forskellige par cystein-beskyttelsesgrupper 
der gjorde selektiv disulfiddannelse muligt.  
 Resumé  
V 
 Derefter blev redox-buffer oxidationsmetoden brugt til at syntetisere seks 
melanocortinanaloger af gurmarin. Disse peptider blev designet på baggrund af en 
strukturel sammenligning af gurmarin og agouti-related protein, en endogen antagonist af 
melanocortin receptorerne. Den C-terminale del af agouti-related protein indeholder flere 
disulfider ligesom det inhibitor cystine knottede gurmarin. Derudover, blev to tetra-
disulfidanaloger af gurmarin designet og syntetiseret baseret på sammenligningen med 
agouti-related protein. Melanocortinanalogerne blev karakteriseret for deres binding til 
melanocortinreceptorerne. Generelt blev det vist, at det er muligt at syntetisere 
gurmarinanaloger, der binder til melanocortinreceptorerne. Analogen med højest affinitet 
for melanocortin 4 receptoren havde en bindingsaffinitet på 500 nM, hvilket er omkring ti 
gange lavere affinitet end den endogene agonist α-melanocyte stimulating hormone.  
 Endeligt blev det vist, at det var muligt at syntetisere melanocortinanaloger af 
det cykliske cystine knottede peptid kalata B1, et plantepeptid hvis to termini er cykliserede. 
Det blev bekræftet med NMR spektroskopi, at disse analoger havde tredimensionelle 
strukturer lignende kalata B1. Det blev vist at én analog bandt til melanocortin 4 receptoren 
med en bindingsaffinitet på 29 nM, hvilket er højere affinitet end α-melanocortin 
stimulating hormone. Analogen var derimod mindre potent end α-melanocortin stimulating 
hormone til at aktivere melanocortin 4 receptoren. Derudover blev det også vist at 
analogerne var meget stabile overfor proteolyse sammenlignet med α-melanocyte 
stimulating hormone. 
 
Alt i alt blev det bekræftet, at det er muligt at grafte melanocortin bindende sekvenser ind i 
cystine knottede peptider ved brug af to forskellige peptider som molekylær platform. 
Disse melanocortin analogers evne til at danne native strukturer blev bekræftet. Derudover 
blev det vist at de syntetiserede peptide kan binde til og aktivere melanocortin 4 receptoren. 
Yderligere var peptiderne proteolytisk stabile. Denne nye melanocortin grafting-metode har 
produceret nye kandidater til udviklingen af lægemidler til behandling af fedme. 
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PREFACE 
This Ph.D. thesis consists of four main chapters. The first chapter describes the 
background of inhibitor cystine knotted peptides and of the melanocortin system. The 
second chapter concerns different synthesis strategies pursued for the synthesis of the 
inhibitor cystine knotted peptide gurmarin. In addition it covers structure determination 
analyses of the synthesised peptides. In the third chapter the design, synthesis and 
functional characterisation of melanocortin analogues of gurmarin is studied. Finally, the 
fourth chapter deals with the design, synthesis, functional and structural characterisation of 
melanocortin analogues of the cyclotide kalata B1. 
The work described in this Ph.D. thesis has been performed at Novo 
Nordisk A/S, Måløv, Denmark, the Department of Micro- and Nanotechnology, Center 
for Nanomedicine and Theranostics, Technical University of Denmark, Kgs. Lyngby, 
Denmark and the Institute for Molecular Bioscience, The University of Queensland, 
Brisbane, Australia. The Ph.D. project was co-financed by the Industrial Ph.D. programme, 
the Danish Agency for Science, Technology and Innovation and the Novo Nordisk R&D 
Science Talent Attraction and Recruitment (STAR) programme. 
 Part of the work described in chapter two was summarised in a poster 
presentation and proceedings paper at the 31st European Peptide Symposium, Copenhagen, 
5-9 September 2010. Another part of the work was accepted for publication in Peptides. 
The work presented in chapter four was submitted for publication. 
 
R. Eliasen, T. L. Andresen, K. W. Conde-Frieboes. Synthesis and Structure Confirmation of the Cysteine Knotted 
Peptide Gurmarin by Selective Disulphide Formation. Proceedings of the 31st European Peptide Symposium, 
Copenhagen, 5-9 September 2010. Ed. M. Lebl, M. Meldal, K. J. Jensen and T. Høeg-Jensen. European 
Peptide Society, 2010. 144-5. Print. 
 
R. Eliasen, T. L. Andresen, K. W. Conde-Frieboes. Handling a tricycle: orthogonal versus random oxidation of the 
tricyclic inhibitor cystine knotted peptide gurmarin. Peptides, in press. 
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4-MBzl; 4-methylbenzyl 
4-PDS; 4,4-dithiodipyridine 
Acm; acetamidomethyl 
ACTH; adrenocorticotropic hormone 
AgRP; agouti-related protein 
Boc; tert-butoxycarbonyl 
CCK; cyclic cystine knot 
CDAP; 1-cyano-4-dimethylaminopyridinium tetrafluroborate 
DCM; dichloromethane 
DIC; 1,3-diisopropylcarbodiimide 
DIPEA; diisopropylethylamine 
DMF; dimethylformamide 
DMSO; dimethylsulfoxide 
DTT; dithiothreitol 
EDTA; ethylenediaminetetraacetic acid 
Fmoc; 9-fluorenylmethyloxycarbonyl 
GSH; reduced glutathione 
GSSG; oxidised glutathione 
HBTU; 2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HFIP; hexafluoroisopropanol 
HOBt; 1-hydroxybenzotriazole 
HPLC; high-performance liquid chromatography 
ICK; inhibitor cystine knot 
MCR; melanocortin receptor 
MS; mass spectrometry 
MSH; melanocyte stimulating hormone 
MT-II; melanotan II 
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MW; molecular weight 
NDP-α-MSH; [Nle4,D-Phe7]-α-MSH 
Nle; norleucine 
NMP; N-methyl pyrrolidone 
NMR; nuclear magnetic resonance 
Pbf; 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl 
PEG; polyethylene glycol 
POMC; pro-opiomelanocortin 
PS; polystyrene 
SPPS; solid phase peptide synthesis 
StBu; tert-butylthio 
tBu; tert-butyl 
TCEP; tris-2-carboxyethylphosphine 
TEA; triethylamine 
TIPS; triisopropylsilane 
TFA; trifluoroacetic acid 
Tris; tris(hydroxymethyl)aminomethane 
Trt; trityl 
UPLC; ultra-performance liquid chromatography 
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1. INTRODUCTION 
1.1 GURMARIN 
 
Gurmarin is a 35 amino acid peptide (Figure 1.1) isolated from the leaves of the plant 
Gymnema sylvestre [1], a woody climber found in south India. The leaves of the plant has 
been used for treatment of type 2 diabetes mellitus in the traditional Ayurvedic medicine 
[2]. The antidiabetic effect is believed to be caused by a group of glycosides named 
gymnemic acids, which lower blood glucose and possibly has a regenerative effect on 
pancreatic beta cells [3,4]. In contrast to gymnemic acids, gurmarin has been found to 
inhibit sweet taste receptors in rodents [1,5], while only a minimal effect has been observed 
in humans [1].  
 
 
Figure 1.1. In the top the primary 
structure of gurmarin is shown. The 
asterisk indicates an N-terminal 
pyroglutamic acid. Below is the NMR 
derived three-dimensional structure of 
gurmarin. PDB ID: 1c4e. 
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The primary structure of gurmarin was first determined by a combination of 
enzymatic digestions and Edman degradation [6], while a similar approach determined the 
connectivity of three disulphides [7]. The three disulphides form an inhibitor cysteine knot 
(ICK) which define the tertiary structure of gurmarin confirmed by two published nuclear 
magnetic resonance (NMR) derived three-dimensional structures (Figure 1.1) [8,9]. The 
neighbouring cysteines in position 17 and 18 make a simple determination of the 
disulphide combination by enzymatic digestion unfeasible due to lack of cysteine-specific 
proteases [6,7]. 
 
1.2 INHIBITOR CYSTINE KNOTTED PEPTIDES 
The ICK is defined by six cysteines forming three disulphides connected as Cys(1-4), 
Cys(2-5) and Cys(3-6), where the numbers refer to the cysteine position from the N-
terminal end. Furthermore, the peptide backbone and the Cys(1-4) and Cys(2-5) 
disulphides form a ring, which is penetrated by the Cys(3-6) disulphide (Figure 1.2) [10].  
 
 
Figure 1.2. A depiction of the 
ICK in gurmarin. The six 
cysteines are numbered 1 to 6 in 
order of their position in the 
sequence from the N-terminal 
end. The ring formed by the 
backbone and the Cys(1-4) and 
Cys(2-5) disulphides are 
highlighted in red. Disulphides 
are shown in yellow. The N-
terminal pyroglutamic acid is 
marked with an asterisk. 
 
ICK peptides have been found in a variety of species like cone snails [11], 
spiders [12], squash [13], potato [14] and in other plants [8]. They all share similar functions 
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as toxins or ion channel inhibitors, which gives rise to the ICK name [10]. A subgroup of 
the ICK peptides that has a similar disulphide pattern but also a cyclic backbone are 
referred to as cyclotides, and their general structure is referred to as the cyclic cystine knot 
(CCK) [15]. These peptides are found in plants where they are believed to function as a 
host defence towards insects and other pests [16-19]. 
Despite their similar function, high sequence diversity besides the six 
cysteines is found in ICK peptides [20-22]. This diversity suggests that it is possible to graft 
functional peptide sequences into the ICK or cyclotide frameworks. Hence, ICK peptides 
would make a suitable scaffold for designing peptide drugs or for agricultural applications 
like crop pest protection [20,23,24]. Besides the sequence diversity, a very high enzymatic, 
thermal and chemical stability is observed in ICK peptides, especially in cyclotides 
[18,19,25]. Since stability often is a concern when developing peptide drugs [26-28], this is a 
huge advantage for the ICK scaffold in peptide drug design. Furthermore, injection is often 
the delivery route of peptide drugs, but this route can be associated with discomfort and 
inconvenience [26,28]. ICK peptides have potential for oral delivery due to their higher 
enzymatic stability and their ability to permeate membranes compared to other peptides 
[29]. Thereby, they might overcome another obstacle in peptide drug development. 
 
1.2.1 Grafting examples in inhibitor cystine knotted peptides 
The grafting principle in ICK peptides has been demonstrated by designing and 
synthesising a chimeric protease inhibiting peptide inhibiting two different proteases [30], 
and by altering the specificity of protease inhibitors [31]. In addition, inhibitors of 
fibrinogen binding and platelet aggregation have been synthesised by grafting RGD 
containing sequences into ICK scaffolds [32]. It has been shown that one of the most 
studied cyclotides, kalata B1 is able to obtain the native CCK fold after substitution of 
amino acids responsible for haemolytic effect of the peptide [33]. Further grafting work 
with kalata B1 has produced analogues that are promising for treatment of angiogenesis 
[34] and inflammatory pain [35], the latter having oral bioavailability. Another cyclotide, 
MCoTI-II has been engineered to produce a foot-and mouth disease virus inhibitor [36].  
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Figure 1.3. Illustration of two oxidation strategies for ICK peptides. a) In a random redox buffer oxidation, 
the reduced cysteines are oxidised to the ICK peptide via multiple scrambled disulphide isomers. The native 
product is expected to be the most thermodynamically favoured product and therefore it is also expected to 
be the most abundant product. b) In an orthogonal oxidation, three pairs of different side chain protection 
groups are selectively removed one at a time and the corresponding disulphides can thus be formed 
selectively one at a time. This ensures that only the native ICK conformation is obtained.  
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1.2.2 Synthesis of inhibitor cystine knotted peptides 
The synthesis of ICK peptides is complicated by the fact that the six cysteines can be 
connected by 15 different disulphide combinations. A common procedure used to fold 
ICK peptides builds on a method using a redox buffer mixture of reduced glutathione 
(GSH) and oxidised glutathione (GSSG) or other low molecular weight (MW) thiol-
disulphide pairs [37]. This procedure is able to re-oxidise reduced proteins into their native 
conformation by disulphide scrambling of non-native disulphides into native, based on the 
hypothesis that the native conformation is the one with the lowest Gibbs free energy [38]. 
The oxidation procedure has been used for the synthesis of a variety of ICK peptides [39-
42] and is illustrated in Figure 1.3a. Another oxidation procedure uses the enzyme protein 
disulphide isomerase that analogously to the redox pair is able to catalyse the scrambling of 
non-native disulphides into native [43,44]. This enzyme has been used to catalyse ICK 
peptides [45], however it does not appear to be widely used in ICK peptide oxidation. 
An enzymatic approach has also been used in the backbone cyclisation of 
cyclotides [46] where immobilised trypsin was used for cyclisation and affinity purification. 
However, the most commonly used principle for backbone cyclisation uses a C-terminal 
thioester to cyclise the backbone via native chemical ligation [47,48]. The C-terminal 
thioester is easily formed using tert-butoxycarbonyl (Boc)-solid phase peptide synthesis 
(SPPS), and the cyclisation and disulphide formation can be done concurrently in a redox 
buffer as described above [49]. The use of HF to cleave peptides from the resin after Boc-
SPPS is a limitation to this strategy. Unfortunately, the C-terminal thioester is not as easily 
incorporated using 9-fluorenylmethyloxycarbonyl (Fmoc)-SPPS, due to low stability 
towards the deprotection conditions used in Fmoc-SPPS. Consequently, Fmoc-compatible 
methods have been developed where the thioester is formed on-resin after the linear 
peptide synthesis [50] or where the side chain protected peptide is cleaved from the resin 
and the thioester formed in solution [51]. The latter method has been adapted for the 
synthesis of cyclotides [52]. 
It has been shown that mature ICK peptide sequences provide sufficient 
information to obtain native structures and disulphide connections [42,45]. However, since 
the formation of native peptide is reduced when urea is added during the oxidation, non-
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covalent interactions and not only the amino acid sequence are affecting the folding into 
native structures [40,42]. In the case of a double chain cysteine rich peptide like insulin, the 
native structure was not obtained when protein disulphide isomerase was used for the 
oxidation [53]. This indicates that insulin is oxidised as linear pro-insulin, which is 
subsequently cleaved into mature insulin. This illustrates that it is not always the case that 
mature peptide sequences contain sufficient information to obtain the native structure. 
Another method to form the disulphides in ICK peptides involves 
orthogonal side chain protection of the involved cysteines [54]. These allow selective 
deprotection and oxidation of the three disulphides as illustrated in Figure 1.3b. Even 
though various orthogonal synthesis pathways have been suggested [55], only few examples 
are reported of such syntheses [56-58].  
The orthogonal oxidation method ensures that only the desired disulphide 
connectivity is produced. Partly orthogonal synthesis methods have been used to confirm 
that native conformations are obtained when using random oxidation of ICK peptides 
[59,60]. NMR spectroscopy has been widely used to determine the three-dimensional 
structure of ICK peptides [24]. However, the NMR determination of the disulphide 
connectivity can be difficult. This was illustrated by a suggested revision of the initial 
structure determination of kalata B1 [61]. The revision was contradicted by a confirmation 
of the initial and generally accepted disulphide connectivity though [62]. Nonetheless, these 
findings suggest that other ways of determining the disulphide connectivity should also be 
pursued. A chemical determination of disulphide connectivity has been described in which 
a partial disulphide reduction is followed by cyanylation of reduced cysteines [63]. This 
produces a mixture of peptides that are first separated by high-performance liquid 
chromatography (HPLC), then selectively cleaved at cyanylated cysteine residues and finally 
analysed by mass spectrometry (MS). In another method inspired by this procedure, 
peptides are partially reduced and reduced cysteines N-ethyl maleimide alkylated, followed 
by a full reduction and reaction with 2-bromoethylamine. The ethylamine alkylation 
produces lysine-like modified cysteines that are amenable to tryptic digestion and thus the 
disulphide connectivity can be determined [64]. These chemical methods to confirm the 
disulphide connectivity provides a supplement to NMR based determination. 
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1.3 THE CENTRAL MELANOCORTIN SYSTEM 
The central melanocortin system is defined as brainstem and hypothalamic neurons 
expressing neuropeptide Y, agouti-related protein (AgRP) or pro-opiomelanocortin 
(POMC) along with their downstream targets expressing melanocortin receptors (MCR) 3 
and 4 [65]. The central melanocortin system is involved in energy homeostasis and appetite 
regulation and consequently it is a target for the development of drugs for treatment of 
obesity [65-67]. 
 
1.3.1 The melanocortin receptors 
The MCRs is a family of five G protein-coupled receptors named in the order of their 
discovery [68-72]. The MC1R is mainly found in melanocyte cells [68,69]. The MC2R is 
found in the adrenal cortex and regulates steroidogenesis [68]. Of the endogenous agonists 
only adrenocorticotropic hormone (ACTH) is able to bind to the MC2R [73]. The MC3R is 
mainly found in the arcuate nucleus of the hypothalamus [70,74] where it is suggested to 
function as an autoinhibitory receptor that downregulates the POMC neuron signalling 
[75,76]. In addition it has been shown that stimulation of the MC3R increases food intake 
in mice [77]. The MC4R is found throughout the brain [71,78] and is known to be involved 
in weight regulation, since obesity is observed both in MC4R deficient humans and mice 
[79,80]. Furthermore, it has been shown that stimulation of the MC4R increases energy 
expenditure, decreases appetite and as a result thereof reduces weight in mice. This was 
illustrated by the lack of response in MC4R knockout mice to stimulation by the MCR 
agonist melanotan II (MT-II) (described below) compared to the response in wild type 
mice [81,82]. The MC5R is distributed throughout the body with high levels found in 
skeletal muscle, brain and exocrine glands and consequently it exerts a variety of functions 
[72,83,84]. 
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1.3.2 Melanocortin receptor ligands  
The endogenous ligands for the melanocortin receptors consists of four agonists, α-
melanocyte stimulating hormone (MSH), β-MSH, γ-MSH and ATCH all derived from the 
precursor POMC (see Figure 1.4a) [85,86] and two antagonists agouti protein [87] and 
AgRP [88].  
 
 
 
Figure 1.4. a) Illustration of POMC and the peptide hormones that are produced from its processing. The 
melanocortin agonists ACTH, α-MSH, β-MSH and γ-MSH are shaded in grey. The other peptides derived 
from POMC are β-lipotropin, corticotropin-like intermediate peptide (CLIP), γ-lipotropin and β-endorphin. 
These peptides will not be discussed in this work, since they are not active on the MCRs. b) The primary 
structures of the four endogenous MCR agonists. The His-Phe-Arg-Trp pharmacophore is highlighted in 
bold. 
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 The four agonists share the His-Phe-Arg-Trp pharmacophore (see Figure 
1.4b) and it has been shown that this tetrapeptide alone is able to activate the MCRs 
(except the MC2R) [89]. Engineering of the endogenous MSH peptides has led to more 
potent and protease stable analogues. Substitution of Met4 to norleucine (Nle) and Phe7 to 
D-Phe in α-MSH produced the highly potent nonselective agonist [Nle4,D-Phe7]-α-MSH 
(NDP-α-MSH) [90], which is often used as a standard in MCR binding and activity assays. 
In another engineering work of α-MSH, Met4 and Gly10 were replaced with cysteines, which 
were oxidised to form a disulphide cyclisation of the pharmacophore [91]. This analogue 
had both increased potency and prolonged activity compared to α-MSH. These two 
analogues were proposed to have stabilised an active conformation of the pharmacophore 
and thereby increased the potency [90,91]. By combining these two approaches MT-II was 
designed. This peptide is a truncated version of NDP-α-MSH (residues 4-10) in which an 
inserted Asp residue in position 5 and a Lys residue in position 10 forms a stabilising 
lactam bridge [92]. As mentioned above, MT-II has been used in a number of studies to 
illustrate the functions of the MCRs. 
 The C-terminal residues 87-132 of the MCR antagonist AgRP contain five 
disulphides in a similar conformation as the ICK [93]. Engineering of this C-terminal part 
produced a 34 residue ICK peptide AgRP(87-120, C105A) with four disulphides (see 
Figure 1.5). Both peptides show high antagonist activity at the MCRs [94]. The fourth non-
ICK disulphide surrounds the loop in which the antagonist binding motif Arg-Phe-Phe 
[95] is present (see Figure 1.6a). Similarly to the engineered cyclic melanocortin agonists 
described above, the disulphide may induce a favourable conformation of the active loop 
for the MCRs. Further engineering of the four disulphide ICK peptide AgRP(87-120, 
C105A) reversed the antagonist activity. This was done by replacing the Arg-Phe-Phe motif 
with the His-D-Phe-Arg-Trp pharmacophore and a consequently a nanomolar affinity 
agonist at the MCRs was obtained [96]. 
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Figure 1.5. Structural 
alignment of AgRP(87-120, 
C105A) (PDB ID: 1mr0) 
coloured in magenta with 
gurmarin (PDB ID: 1c4e) 
coloured in green. The 
active loop in AgRP(87-120, 
C105A) is in the bottom and 
stabilised by the fourth non-
ICK disulphide, which is not 
present in gurmarin. The 
aligned sequences of 
AgRP(87-120; C105A) and 
gurmarin are shown at the 
bottom with disulphides 
indicated as lines. The 
asterisk indicates an N-
terminal pyroglutamic acid. 
 
 
 
 
 
 
 
 
1.3.3 Development of melanocortin peptide pharmaceuticals 
Some inconclusive studies on body fat reduction have been reported when ACTH(4-10) 
was administered intranasally [97,98]. In normal weight humans, fat mass reduction and 
weight loss was observed, while no significant effect was observed in overweight humans. 
The lack of response could be explained by changes in the MC4R reported in some obese 
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people [80]. Another explanation is a possible MSH resistance observed in obese people 
[99], thus suggesting that higher doses or more potent and selective compounds are 
necessary.  
 
 
Figure 1.6. An illustration of the grafting principle in this work. a) The active loop in AgRP(87-120, C105A) 
(PDB ID: 1mr0) coloured in magenta aligned with the similar loop in gurmarin (PDB ID: 1c4e) coloured in 
green. The side chains of the binding residues Arg-Phe-Phe in AgRP(87-120, C105A) are shown. b) The side 
chains of residues 26-31 in the gurmarin loop are shown. c) A model of the His-Phe-Arg-Trp pharmacophore 
mutation in the gurmarin loop at residues 27-30. The four residues are coloured in grey. 
 
Despite many years of research, no melanocortin drugs are in advanced 
human trials for obesity [67,100]. It has been proposed that this could be due to the high 
similarity between the MCRs, and consequently side effects due to lack of selectivity for 
one receptor [100], or due to the often observed low half-life of peptides in vivo [101,102]. 
It has also been suggested that a fine tuning of the selectivity in order to achieve an optimal 
signalling e.g. of the MC3R and MC4R could improve the outcome of clinical studies with 
melanocortin drugs [67]. However, the lack of knowledge of the interplay between the 
MC3R and MC4R in regulating appetite and energy homeostasis is a limitation to the 
pursuit of this hypothesis. 
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The non-selective MCR agonists MT-II and its C-terminal acid analogue 
[103] have been evaluated in phase 1 clinical trials for MCR mediated penile erection and 
sexual desire. The compounds were effective in these trials, and the most common side 
effects observed were flushing, nausea, stretching/yawning, headache, hypertension, taste 
disturbance and feeling hot [104-108]. Since the agonists were not selective, it is not known 
which MCR is responsible for mediating the observed effects. In addition, it has previously 
been suggested that hypertension effects of γ-MSH are exerted through a non-MCR 
mediated pathway [109]. The side-effects in the trials were observed at a mild level and 
might be acceptable when administering a drug occasionally for treatment of sexual 
disorders. However, when stimulating the MC4R chronically for treatment of obesity, these 
side effects along with the potential increase in penile erection and sexual desire may not be 
deemed acceptable. Consequently, there is a need for more stable and selective MC4R 
ligands if this pathway should be used for treatment of obesity.  
 
1.4 PROJECT AIMS 
It is possible that gurmarin based melanocortin analogues may overcome some of the 
limitations of current analogues described in this chapter. Due to the ICK framework, the 
peptides will most likely be more stable towards enzymatic degradation than native MSH-
peptides. In addition, they could possibly also be more selective due to a more stabilised 
conformation within the ICK framework. Furthermore, it is possible that their non-
melanocortin nature could reduce some of the side-effects that have been observed, if 
these are exerted on other receptors than the MCRs and not by the His-Phe-Arg-Trp 
pharmacophore. 
Due to the ICK nature of the engineered AgRP(87-120, C105A) a structural 
alignment with gurmarin was made. This indicated that an inter-cysteine loop was present 
in gurmarin with high similarity to the active loop in AgRP(87-120, C105A) (see Figure 
1.5). 
 Consequently, the aim of the project was to pursue the grafting principle by 
synthesising melanocortin analogues of gurmarin. This was done by engineering the His-
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Phe-Arg-Trp pharmacophore into gurmarin (illustrated in Figure 1.6) in a similar fashion as 
was described for AgRP(87-120; C105A) [96]. The synthesised analogues were evaluated 
for their binding to the MCRs. Before synthesising melanocortin analogues of gurmarin a 
stable gurmarin synthesis route was established by comparing orthogonal disulphide 
formation with random redox oxidation of the disulphides in gurmarin. 
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2. SYNTHESIS OF GURMARIN 
2.1 INTRODUCTION 
This chapter will present the work done on optimising the synthesis of gurmarin and 
confirmation of the disulphide connectivity. All peptide structures synthesised are given a 
number and a complete list of the structures is found in Appendix A. The work in this 
chapter has led to one poster presentation (Appendix B) and proceedings paper (Appendix 
C) along with one paper accepted for publication (Appendix D). An experimental section is 
found at the end of this chapter.  
 
2.2 FIRST SYNTHESIS STRATEGY 
The initial strategy involved acetamidomethyl (Acm) protection of all six cysteines (Table 
2.1). Acm-protected cysteines can be oxidised to disulphides using iodine, which forms an 
iodide activated cysteine that is able to react with another Acm protected or iodide 
activated cysteine [110,111]. The advantage of this method is a fast oxidation, while the 
lack of control over which disulphides are formed is a drawback.  
 
Table 2.1. Positions of cysteine side chain protection groups in the first strategy and the partially orthogonal 
gurmarin oxidation strategy. The lower case letter refers to the different synthesis procedures pursued for the 
synthesis of gurmarin (1). 
Procedure Cys3-18 Cys10-23 Cys17-33 
1a Acm Acm Acm 
1b Acm Acm Trt 
1c Acm Trt Acm 
1d Trt Acm Acm 
 
Linear gurmarin (1a) was synthesised on an automated peptide synthesiser 
using standard Fmoc-SPPS chemistry with and without use of microwaves for coupling 
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and deprotection. The MW of the main product was 18 Da lower than expected. This was 
suggested to be due to aspartimide formation of the Asp16-Cys(Acm)17 bond (Figure 1.1), 
since it has been reported that this sequence is prone to aspartimide formation [112]. 
Another explanation could be aspartimide formation of Asp7 or Asp30, however the -18 
Da MW appeared after coupling of Asp16. To confirm the aspartimide hypothesis, a 
gurmarin analogue with Asp16 substituted with Ala was synthesised. In this synthesis only 
the expected MW was observed confirming the aspartimide formation of Asp16. 
 
 
Figure 2.1. Treatment of the aspartimide peptide with NaOH. In the top left are the aspartimide and non-
aspartimide peptide UPLC (ultra-performance liquid chromatography) chromatogram and mass spectra of the 
triple charged peptides (non-aspartimide exp. MW: 1390.64). Below are the peptides after treatment with 
NaOH. The four peaks observed are due to the four isomers produced from hydrolysis of the aspartimide as 
depicted to the right. R indicates surrounding amino acids The gradient used on UPLC are 20-60% of 70:30 
acetonitrile:water against 10% acetonitrile in 0.2 M Na2SO4, 0.04 M H3PO4, pH 3.5 over 8 min.  
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The aspartimide was stable when dissolving the peptide and during 
purification. Treatment of a mixture of aspartimide peptide and non-aspartimide peptide 
with NaOH gave four products all with the same mass as the non-aspartimide peptide. 
This corresponds to D- and L- stereoisomers of alpha and beta branched peptide as 
illustrated in Figure 2.1 that shows the NaOH treatment of reduced gurmarin with Asn27 
substituted for Ala [113].  
To reduce the aspartimide formation, the protection groups of Cys17 and 
Cys33 were changed to trityl (Trt), since the Asp-Cys(Trt) bond should be less prone to 
aspartimide formation [112]. In addition, the introduction of a second pair of cysteine 
protection groups made selective formation of the first disulphide possible. It has 
previously been shown that a partially orthogonal oxidation of three disulphides in a non-
ICK peptide, where two disulphides are formed first and the third disulphide is formed 
selectively afterwards produces the expected product [114]. It was suggested that the 
formation of the correct disulphide combination was induced by reducing the possible 
disulphide combinations from fifteen to three. In addition, positioning of the orthogonal 
protection group on cysteines that would normally form non-native disulphides based on 
experience was proposed to increase the yield. Consequently, it is possible that the selective 
formation of the first disulphide in gurmarin induces the correct formation of the final two 
disulphides. 
Linear peptide 1b (Table 2.1) was synthesised on an automated microwave 
peptide synthesiser using standard Fmoc-SPPS chemistry. As expected, the aspartimide 
formation was reduced but not eliminated by introducing Cys(Trt) as residue 17. The 
peptide was cleaved from the resin using trifluoroacetic acid (TFA) and scavengers, which 
removed Trt protection groups on Cys17 and Cys33 concurrently and did not affect the 
Acm-protected cysteines. The first disulphide was formed by air oxidation in an aqueous 
tris(hydroxymethyl)aminomethane (Tris)-HCl buffer, pH 7.8 with 2 vol% 
dimethylsulfoxide (DMSO). The final two disulphides were formed by iodine oxidation 
using 20 eq. of iodine in 1:4 water:methanol. Only one product with the expected MW was 
observed and isolated in yields from 0.25-0.5% based on the loading of the resin. 
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To investigate the disulphide connectivity of 1b, a chymotrypsin cleavage of 
the peptide was done. As illustrated in Figure 2.2, a chymotrypsin cleavage of gurmarin 
should not produce multiple fragments, since the fragments would be connected by the 
disulphides. However, a mass spectrum of the chymotrypsin cleavage of 1b showed two 
products corresponding to residues 1-13 and 14-35 as illustrated in Figure 2.2. Since the 
Cys17-Cys33 disulphide is formed selectively, the depicted disulphide connectivity with two 
non-native disulphides is the only possible combination.  
 
 
Figure 2.2. The cleavage 
sites for chymotrypsin (red) 
and thermolysin (green) in 
gurmarin is highlighted on 
top. Chymotrypsin cleaves 
the C-terminal peptide bond 
of aromatic amino acids. 
Thermolysin cleaves the N-
terminal peptide bond of 
hydrophobic acids. The 
asterisk indicates an N-
terminal pyroglutamic acid 
residue. In the middle are two 
non-native gurmarin 
fragments observed in a 
chymotrypsin cleavage of peptide 1b. The bottom shows the observed mass spectra of the fragments from 
the chymotrypsin cleavage. The calculated mass of the mono-disulphide fragment is 1546.70 and the 
calculated mass of the bis-disulphide fragment is 2677.20 and 2677.22 calculated from the triple and double 
charged peptide respectively. 
 
Consequently, the synthesis strategy 1b did not produce gurmarin (1) but a 
disulphide isomer of gurmarin (2). The pH during the chymotrypsin cleavage was 7.8 and 
consequently scrambling of the disulphides was a possibility. However, only the mass peaks 
depicted in Figure 2.2 were observed, which indicate that scrambling did not occur. 
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Similar synthesis strategies were used for peptide 1c and 1d, which only 
differed in the position of the Trt protection groups as shown in Table 2.1. Since Cys17 
was Acm-protected in these peptides aspartimide was observed in both syntheses and the 
overall yields of the syntheses were less than 0.1%. 
 
Table 2.2. A list of the fragments observed by thermolysin cleavage of peptides 1b-d. The asterisk indicates 
an N-terminal pyroglutamic acid residue. 
 
 
Peptides 1b-d were cleaved with thermolysin to investigate the disulphide 
connectivity. The possible cleavage sites for thermolysin in gurmarin are shown in Figure 
2.2. The observed masses of the fragments from the cleavage are listed in Table 2.2. For all 
three peptides, the major fragments were non-native. In peptide 1c, a fragment containing 
the selectively formed Cys10-Cys23 disulphide was found though. In peptide 1d, two 
fragments containing only native disulphides were observed: the Cys10-Cys23 fragment 
also observed in peptide 1c, and a fragment containing the final two disulphides. Since the 
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Cys3-Cys18 disulphide was formed selectively in peptide 1d, the final disulphide must be 
the native Cys17-Cys33 and consequently native gurmarin (1) was produced in the synthesis 
of peptide 1d. However, the amounts of the native fragments were lower than the amounts 
of the non-native fragments also observed. Consequently, native gurmarin was a by-
product of this synthesis. The peptide obtained from the 1c procedure was another 
disulphide isomer of gurmarin (3), while the major product obtained from the 1d procedure 
was a third disulphide isomer of gurmarin (4). 
This work with the partially orthogonal synthesis of gurmarin and 
thermolysin cleavage of the peptides was presented as a poster shown in Appendix B and 
published as a proceedings paper, which is found in appendix C. 
 
2.3 REDOX BUFFER OXIDATION STRATEGY 
Since the first synthesis strategy only produced gurmarin in very small amounts not 
separable from the non-native disulphide isomers of gurmarin also produced, a new 
random redox oxidation strategy was attempted. This strategy uses a low MW thiol-
disulphide pair to induce scrambling of the disulphides in gurmarin until the most 
thermodynamically favourable conformation is obtained as described in the introduction. 
The redox buffer oxidised gurmarin is called peptide 1e. 
 Linear peptide 1e was synthesised on an automated microwave peptide 
synthesiser using standard Fmoc-SPPS chemistry with all cysteines Trt protected. The 
aspartimide formation was not eliminated by the introduction of Cys(Trt) in position 17. 
Consequently, 0.05 M 1-hydroxybenzotriazole (HOBt) was added to the piperidine solution 
used for Fmoc-deprotection, since this has been shown to suppress aspartimide formation 
[112,115]. As depicted in Figure 2.3, the addition of HOBt almost eliminated the 
aspartimide formation. 
 Following preparative HPLC purification, the peptide was oxidised in a 0.1 
M Tris-HCl (pH 7.8), 1 mM ethylenediaminetetraacetic acid (EDTA), 2 mM GSH, 2 mM 
cystamine, 35 vol% DMSO, 6 vol% 2-dodecyloxyethanol buffer that had previously been 
optimised for the synthesis of the cyclotide cycloviolacin O2 [52]. The peptide was oxidised 
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for 48 hours in 0.01 mM concentration. Subsequently, analysis by UPLC and MS indicated 
that one product was formed with the expected MW. However, the preparative HPLC 
purification was complicated by the viscous detergent 2-dodecyloxyethanol. 
 
 
Figure 2.3. Aspartimide formation with and 
without HOBt addition during Fmoc-
deprotection. The mass spectra correspond to 
triple charged gurmarin (exp. MW: 1404.97). 
   
 
 
 
 
 
 To improve the oxidation and to facilitate the final purification, the redox 
buffer was optimised. Nine different conditions were tested (Table 2.3). The conditions 
were chosen based on a review on disulphide bond formation in peptides [54] and the 
buffer used initially. The detergent 2-dodecyloxyethanol was not included in the oxidations. 
It was added to favour solubility of folded peptides with solvent exposed hydrophobic 
residues [52]. However, since other reported redox oxidations of ICK peptides did not 
include detergents, it was anticipated that gurmarin would be able to fold with no detergent 
added. This would ultimately make the purification less complicated.  
 Not surprisingly, the yields were higher in the Tris buffer because of the 
higher pH and no intermolecular disulphide bonds were observed in either concentration 
tested. The addition of EDTA suppressed the oxidation. In the initial report on GSH-
GSSG oxidation, EDTA was added in order to reduce variations in the oxidation, which 
was proposed to be caused by copper ions. When EDTA was present without GSH and 
GSSG, the oxidation was suppressed similarly to what was observed in this experiment 
[37]. DMSO increased the oxidation yield, however only minor differences were observed 
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between 20 vol% and 10 vol% after 72 h. The 1:1 ratio of GSH:GSSG was superior to the 
1:10 ratio and cystamine was superior to GSSG. This is consistent with the report that 
cystamine is a more powerful oxidation agent than GSSG [116].  
 
Table 2.3. The conditions used in the buffer optimisation. The peptides were oxidised for 72 h. 
Peptide concentration Buffer 
0.01 mM 0.1 M ammonium acetate (pH 6.5) 
0.01 mM 0.1 M Tris-HCl (pH 7.8) 
0.01 mM 0.1 M ammonium acetate (pH 6.5), 1 mM EDTA 
0.01 mM 0.1 M ammonium acetate (pH 6.5), 20 vol% DMSO 
0.01 mM 0.1 M ammonium acetate (pH 6.5), 10 vol% DMSO 
0.01 mM 0.1 M ammonium acetate (pH 6.5), 1 mM GSH, 0.1 mM GSSG 
0.01 mM 0.1 M ammonium acetate (pH 6.5), 1 mM GSH, 1 mM GSSG 
0.01 mM 0.1 M ammonium acetate (pH 6.5), 1 mM GSH, 0.1 mM cystamine 
0.02 mM 0.1 M ammonium acetate (pH 6.5) 
 
Since the oxidation buffer containing cystamine gave the highest amount of fully oxidised 
peptide, peptide 1e was oxidised using 0.1 M Tris-HCl (pH 7.8), 1 mM GSH, 1 mM 
cystamine as redox buffer. DMSO was not included in the buffer, since the buffer 
optimisation indicated that the DMSO oxidation mechanism was inferior to the 
GSH:cystamine facilitated oxidation, from which fully oxidised peptide was obtained.  
Figure 2.4 shows UPLC chromatograms illustrating the progress of the oxidation. The 
purified yield of reduced peptide was 24.7%. The yield of the oxidation and purification 
was 57.1% and consequently, the overall yield of peptide 1e was 14.1%.  
 
2.4 STRUCTURE CONFIRMATION 
Since the redox buffer oxidation does not provide control over the disulphide connectivity, 
15 possible combinations can be obtained when the peptide contains six cysteines. 
Consequently, a chemical determination of the disulphide connectivity mentioned in the 
introduction was pursued [63]. 
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Figure 2.4. UPLC chromatograms 
showing the progress of the redox buffer 
oxidation. The gradient is 5-60% of 0.05% 
TFA in acetonitrile against 0.05% TFA in 
water over 3.5 min. 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.1 Partial reduction and cyanylation 
The principle of the method is outlined in Figure 2.5. The advantage of the method is that 
it makes it possible to distinguish between neighbouring cysteines. This is not possible 
when using traditional proteolytic approaches due to lack of cysteine specific proteases. In 
addition, the reduction and cyanylation is done at pH 3, which reduce the possibility of 
disulphide scrambling of the peptide. 
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Figure 2.5. An example of the chemical determination of the disulphide connectivity. A) The peptide is 
partially reduced using tris-2-carboxyethylphospine (TCEP) producing a mixture of peptides that are fully 
oxidised,  has two disulphides,  one disulphide or are fully reduced. In this example the Cys10-23 disulphide is 
reduced. B) The reduced disulphides are cyanylated using 1-cyano-4-dimethylaminopyridinium 
tetrafluroborate (CDAP). C) After HPLC separation, the peptides are cleaved on the N-terminal bond of 
cyanylated cysteines using methylamine. D) The peptides are fully reduced using TCEP and analysed by MS. 
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 The reduction and cyanylation of gurmarin was optimised by varying the 
reaction times and the amounts of TCEP in order to achieve the highest amount of mono 
and double reduced and cyanylated gurmarin species. However, the changes mostly 
affected the amounts of fully reduced and fully oxidised peptides. Subsequently, the 
separation of the peptides was optimised using different HPLC systems and gradients. 
Finally, the cleavage at the cyanylated cysteines was optimised by using methylamine 
instead of ammonia and by adding guanidinium chloride to the cleavage to denature the 
peptide. 
 Peptide 1e was reduced for 30 minutes using 30 eq. of TCEP. The reduced 
cysteines were cyanylated using 1200 eq. of CDAP. The partially reduced and cyanylated 
peptides were purified using 20-30% acetonitrile against 0.1% TFA in water over 30 min 
on an analytical HPLC and manual fractionation (see Figure 2.6). 
 
 
Figure 2.6. Analytical scale HPLC purification of reduced and cyanylated peptide 1e. The nomenclature in 
the zoomed insertion refers to the observed species in the fractions. o; oxidised peptide 1e, 1; mono reduced 
and cyanylated peptide 1e, 2; double reduced and cyanylated peptide 1e, r; fully reduced and cyanylated 
peptide 1e. The gradient was 20-30% acetonitrile against 0.1% TFA in water over 30 min. 
 
 In general, the fractions were not very pure and the amount of peptide was 
low, which complicated the subsequent MS analysis. The two peaks containing double 
reduced and cyanylated gurmarin (Figure 2.6) were the most pure, and consequently these 
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were cleaved with aqueous methylamine containing guanidinium chloride. The sequence 
and mass spectra of the fragments observed are shown in Figure 2.7. The fragments found 
in the two peaks were shown to contain the Cys10-23 disulphide and the Cys17-33 
disulphide. From these results, it can be deduced that the third disulphide must be the 
Cys3-Cys18 confirming the native disulphide connectivity. 
  
 
Figure 2.7. Sequence and mass spectra of the observed fragments found after methylamine cleavage of 
double reduced and cyanylated gurmarin. Cys10-23 and Cys17-33 are native disulphides while Cys23-33 is a 
non-native disulphide. 
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Low purity and concentration of the purified peptide fragments, which is 
responsible for low resolution mass spectra, gives rise to some uncertainty of the accuracy 
of the disulphide determination though. In addition, when the analysis was repeated a non-
native Cys23-33 fragment was found as shown in Figure 2.7. This either means that 
multiple disulphide combinations are present in peptide 1e or that scrambling occurs in the 
assay despite the low pH that should prevent this. 
 
2.4.2 Thermolysin cleavage 
Due to the complicated and laborious separation of the cyanylated fragments described 
above, a different attempt was made to investigate the disulphide connectivity of peptide 
1e. As shown in Figure 2.2, a thermolysin cleavage of gurmarin would produce a fragment 
containing the Cys10-23 disulphide (8) and a fragment containing the other two disulphides 
(6 or 7).  
 The MS analysis of a thermolysin cleavage of peptide 1e is shown in Figure 
2.8. Only two peaks with disulphide containing fragments were observed; one with the 
Cys10-23 disulphide (8) and another containing the bis-disulphide fragment (6 or 7). 
However, it is not possible to distinguish the connectivities of Cys17 and Cys18. 
Consequently, peptide 1e either has the native disulphide connectivity or a non-native 
Cys3-17, Cys18-33 connectivity. This possible non-native disulphide combination is a 
fourth disulphide isomer of gurmarin (9). 
 Since the thermolysin cleavage was done at pH 6.5, disulphide scrambling is a 
possibility as it was in the chymotrypsin cleavage of peptide 1b. But since only two 
disulphide-containing fragments were found, it is not likely that scrambling had occurred 
during the cleavage. 
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Figure 2.8. On top is the HPLC-MS 
analysis of the thermolysin cleaved 
peptide 1e. The four major peaks in 
the chromatogram are numbered 
according the number of the 
observed fragment and the 
corresponding mass spectra are 
shown. Below is a list of the observed 
fragments obtained from the cleavage 
and their theoretical masses. The 
observed bis-disulphide fragment has 
two possible disulphide connectivities 
as shown (fragment 6 or 7). The peak 
indicated with 1e is non-cleaved 
gurmarin. The asterisk indicates an 
N-terminal pyroglutamic acid. 
 
 
 
 
 
 
 
 
 
2.4.3 Fragment synthesis 
To investigate the disulphide connectivity of the bis-disulphide fragment (6 or 7) in Figure 
2.8, the two bis-disulphide fragments were synthesised as a linear peptides with the two 
cysteine pairs Trt and Acm protected (10 and 11). This allowed for selective disulphide 
formation of both the native fragment 6 and non-native fragment 7 disulphide connectivity 
showed in Figure 2.8. The peptides were oxidised using the same conditions as employed 
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in the first synthesis strategy described in section 2.2. It was expected that a thermolysin 
cleavage of peptides 10 and 11 would produce fragments 6 and 7 respectively, however 10 
and 11 were not cleaved by thermolysin. This was suggested to be due to these short 
fragments containing two disulphides. As a consequence, they are most likely locked in a 
conformation that does not favour the interaction of thermolysin with the cleavage sites. 
 To overcome the thermolysin cleavage problem, two gurmarin analogues 
were synthesised with Cys10 and Cys23 substituted with alanine using the same synthesis 
strategy as described above. The first analogue (12) had two native disulphides, while the 
second analogue (13) had two non-native disulphides as in fragment 7. These two 
analogues were cleaved with thermolysin to produce fragment 6 and 7. The thermolysin 
cleaved peptides 12 and 13 were co-injected with thermolysin cleaved peptide 1e on both 
UPLC and HPLC-MS, but it was not possible to distinguish the native fragment 6 from the 
non-native fragment 7 using these methods since the fragments co-eluted. 
 
2.5 ORTHOGONAL SYNTHESIS STRATEGY 
To overcome the uncertainty of the disulphide connectivity an orthogonal synthesis 
strategy as outlined in (Figure 1.3b) was pursued. Besides the Trt and Acm protection 
groups already mentioned, tert-butylthio (StBu) which can be removed using reduction 
agents as mercaptoethanol, dithiothreitol (DTT) or TCEP [117,118] and 
monomethoxytrityl (Mmt), which can be removed by dilute TFA and scavengers [119] was 
used as cysteine protection groups. 
A number of different conditions were tested for deprotection and oxidation 
of the cysteines as outlined in Table 2.4 and Table 2.5. In addition, different resins were 
used to investigate their effect on deprotection and on-resin oxidation. Finally, a number of 
different combinations of the protection groups were synthesised as outlined in Table 2.6. 
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Table 2.4. Deprotection methods used in the orthogonal oxidation strategy.  
Method Protection group Deprotection conditions 
I StBu 10.1 ml 80:20:1 NMP:mercaptoethanol:DIPEA, 3 x >5 h 
II StBu 50 eq. DTT in 10 ml dioxane, 2 x >5 h 
III StBu 20.2 ml 80:20:1 DCM:mercaptoethanol:DIPEA, 3 x >5 h 
IV StBu 80 eq. DTT, 5 eq. DIPEA in 20 ml water, 5 x 24 h 
V Mmt 10 ml 70:27:3 HFIP:DCM:TIPS, 2 x 15 min 
VI Mmt 10 ml 94:4:2 DCM:TIPS:TFA, 5 x 4 x 5 min 
VII Mmt 10 ml 95:4:1 DCM:TIPS:TFA, 3 x 4 x 5 min 
VIII Mmt 10 ml 95:4:1 DCM:TIPS:TFA, 10 x 5 min 
IX StBu 10.1 ml 80:20:1 NMP:mercaptoethanol:DIPEA, 3 x 60 min, 60°C 
X StBu 10.1 ml 80:20:1 NMP:mercaptoethanol:DIPEA, 3 x 24 h 
XI Mmt 10 ml 95:4:1 DCM:TIPS:TFA, 10 x 2 min 
NMP; N-methyl pyrrolidone. DIPEA; diisopropylethylamine. DCM; dichloromethane. HFIP; 
hexafluoroisopropanol. TIPS; triisopropylsilane. Eq. are compared to resin loading. Unless otherwise stated, 
the deprotection was done at room temperature. 
 
Table 2.5. Oxidation methods used in the orthogonal oxidation strategy. 
Method Oxidation conditions 
XII 10 eq. TEA in 20 ml NMP, 48 h 
XIII 10 eq. 4-PDS in HPLC eluents, 0.05 mM peptide, 48 h 
XIV 100 eq. I2 in 4:1 acetic acid:HPLC eluents, 0.5 µM peptide, 2 h 
XV 10 eq. 4-PDS in 20 ml NMP, >5 h 
XVI 1 eq. 4-PDS in 20 ml NMP, >5 h 
XVII 0.5 eq. 4-PDS in 20 ml NMP, >5 h 
XVIII 20 ml 4:1 NMP:DMSO, 4 h 
XIX 10 eq. 4-PDS in HPLC eluents diluted with water, 0.05 mM peptide, 2 h 
XX 100 eq. I2 in 4:1 acetic acid:HPLC eluents, 0.05 mM peptide, 2 h 
TEA; triethylamine. 4-PDS; 4,4-dithiodipyridine. HPLC eluents were approximately 69.9:30:0.1 
water:acetonitrile:TFA.  
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Table 2.6. Overview and nomenclature of the conditions used in the orthogonal syntheses. Only the 
protection groups that were deprotected in the respective procedures are mentioned. 
Proce-
dure 
Linker and resin Protection 
group 
Position Deprotection 
method 
Oxidation 
method 
1f Wang-PS StBu C3-18 I, II - 
1g NovaSynTGT StBu C3-18 I, II - 
1h Wang-TentaGel StBu C3-18 I, II - 
1i 2-ClTrt-PS StBu C3-18 I, II - 
1j Wang-PS StBu C10-23 I, II XII 
1k Wang-PS StBu C17-33 I, II XII 
1l HMPB-Chemmatrix StBu C10-23 III, IV XII 
1m HMPB-Chemmatrix Mmt C10-23 V XII 
1n Wang-Chemmatrix Mmt C10-23 VI XII 
1o Wang-Chemmatrix Mmt, Trt, Acm C10-23, C17-33, C3-18 V, VII XII, XIII, XIV 
1p Wang-Chemmatrix Mmt C10-23 VII, VIII XII 
1q Wang-PS Mmt C10-23 VII, VIII XII 
1r Wang-PS Mmt C10-23 VIII XV 
1s Wang-PS StBu, Mmt C10-23, C17-33 IX, VIII XV, XV 
1t Wang-PS StBu C17-33 IX XVI 
1u Wang-PS StBu C17-33 X XVII 
1v Wang-PS StBu, Mmt C17-33, C10-23 X, XI XVIII, XVIII 
1w Wang-PS StBu, Trt, Acm C10-23, C17-33, C3-18 X XVIII, XIX, XX 
 
2.5.1 First orthogonal strategy 
In the first orthogonal strategy StBu was used as cysteine side chain protection group for 
the first disulphide. The first disulphide would be oxidised on resin and the final two in 
solution after cleavage from resin using Trt and Acm for the final two disulphide pairs. The 
deprotection conditions, resins, resin linkers and positions attempted are shown in Table 
2.6, peptide 1f-1l. 
 In the first attempt, four different resins were used to evaluate their effect on 
the deprotection (peptide 1f-1i). The polyethylene glycol (PEG) cross-linked resins used in 
peptide 1g and 1h were expected to improve the deprotection because of better swelling 
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abilities [120,121]. However, the best deprotections and crude synthesis yields were 
observed for the Wang-polystyrene (PS) resin.  
 Secondly, the StBu deprotection was evaluated on the three cysteine pairs 
(peptide 1f, 1j, 1k). The C10-23 position was found superior followed by the C17-33 
position. In addition, the mercaptoethanol deprotection (I) was found superior to the DTT 
deprotection (II). The deprotected cysteines in peptide 1j and 1k were air oxidised on resin 
using TEA in NMP (XII). 
 Since not all StBu was deprotected in peptide 1j another PEG cross-linked 
resin was investigated (peptide 1l), the volume of deprotection mixture was increased and 
the solvent changed to DCM (III). Various C-terminal deletion peptides were observed 
using this resin, but the deprotection and oxidation was improved. The synthesis was 
repeated with triple-coupling of the first residue followed by capping, which reduced the 
formation of deletion peptides. Surprisingly, the peptide was not deprotected in the 
repeated synthesis but a +18 Da MW was observed. This was expected to be ring opening 
of the N-terminal pyroglutamic acid residue induced by DIPEA, since it was only observed 
when DIPEA was present during the deprotection. The deprotection was ultimately 
achieved by multiple repeated deprotections with large excess of DTT (IV).  
 
2.5.2 Second orthogonal strategy 
Because of the problems with reproducibility of the StBu deprotection Mmt protection was 
pursued instead (peptide 1m-1r). An initial attempt to deprotect Mmt with HFIP in peptide 
1m was unsuccessful. To investigate the deprotection a small amount of resin was reacted 
with a small amount of 3-maleimidopropionic acid in 10:1 NMP:DIPEA. No alkylation 
was observed, which most likely was due to no Mmt deprotection.  
 In a new synthesis, the resin was replaced by a PEG cross-linked resin with a 
Wang linker, which removed the C-terminal deletions (peptide 1n). Mmt was deprotected 
with 2% TFA (VI). The colour became dark orange during the deprotections. Between 
each set of four deprotections the resin was washed with DCM-NMP-NMP-DCM to 
quench the TFA and remove the colour to better be able to evaluate the deprotection 
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based on the intensity of the colour. In the oxidation two disulphides were formed, most 
likely because the multiple TFA deprotections also deprotected the Trt protection groups. 
In addition, less peptide was observed which could be due to the peptide being cleaved 
from the resin during the deprotections. 
 A new synthesis was made (peptide 1o) and the HFIP deprotection was 
pursued once more followed by oxidation to ensure that the lack of maleimide alkylation 
observed in peptide 1m in fact was due to no deprotection by HFIP. Since no oxidation 
was observed, it was confirmed that the HFIP deprotection (V) was unsuccessful. A 
deprotection with 1% TFA and fewer repetitions was made (VII) and the peptide was 
oxidised. Using this method, half of the peptide was deprotected and oxidised, while the 
other half was not deprotected. Consequently, the deprotection and oxidation was 
repeated, which produced the fully mono-oxidised peptide. The mono-oxidised peptide 
was cleaved and purified. Because of many by-products only low amounts of pure peptide 
was isolated. Based on to the resin loading 1% peptide was isolated. The Trt-protected 
cysteines were deprotected during peptide cleavage, while the Acm-protected cysteines 
were unaffected. The Trt-deprotected cysteines were oxidised with 4-PDS (XIII) and the 
peptide was purified. The yield of the second oxidation and purification was 7%. The final 
oxidation of the Acm-protected cysteines was done using iodine (XIV). However, only low 
amounts of fully oxidised peptide were observed and it was not possible to isolate the 
desired product. 
 The synthesis was repeated using the same resin (peptide 1p) and a Wang-PS 
resin (peptide 1q). In the latter synthesis, fewer by-products were observed, but no 
oxidation was observed, since Mmt was not deprotected when using the same conditions as 
previously (VII). Consequently, the deprotection was repeated without intermediate NMP 
washes (VIII) and the peptides were oxidised (XII). The peptides were cleaved and purified 
but no pure fractions were observed. 
 As an attempt to reduce the by-products and improve the oxidation, a new 
peptide (1r) was synthesised and deprotected using the same conditions as peptide 1q. The 
peptide was oxidised with 10 eq. 4-PDS on resin (XV), but two disulphides were formed. 
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This was suggested to be due to Trt being affected either by the TFA deprotection or by 
the 4-PDS oxidation. 
 
2.5.3 Third orthogonal strategy 
Since the conclusion from the experiments described above was that the Mmt and Trt 
protection groups could not successfully be used orthogonal to each other using the 
attempted deprotection conditions, a new strategy was proposed. In this strategy, StBu was 
reintroduced as first set of protection groups, followed by Mmt and finally Acm. This 
choice of protection groups would make three on-resin disulphide formations possible 
(peptide 1s-1v). 
 To overcome the previously observed reproducibility issues with 
mercaptoethanol deprotection of StBu a new bottle of mercaptoethanol was purchased. In 
addition, microwave heating was attempted to facilitate the deprotection (IX). Peptide 1s 
was successfully StBu deprotected using these conditions and oxidised using 10 eq. 4-PDS 
on resin (XV). Mmt was deprotected using 1% TFA without NMP washes and oxidised on 
resin (IV). Instead of formation of the second disulphide a product with an extra mass of 
220 Da was observed, which indicated that both cysteines had reacted with 4-PDS and 
thereby disulphide formation was blocked.  
 It was proposed that the Cys17-33 disulphide was difficult to form on resin 
because of the close proximity of Cys33 with the resin. To overcome this, the Cys17-33 
disulphide was formed first in peptide 1t using only 1 eq. of 4-PDS (XVI). This time the 
microwave heated deprotection did not fully deprotect StBu and consequently the 
deprotection was repeated twice. This lack of deprotection was probably due to the change 
in position of the protection groups.  
The oxidation produced two disulphides, which was initially considered to be 
due to the many deprotections at elevated temperature affecting the Mmt protection 
groups. The synthesis was repeated (peptide 1u), the peptide was deprotected at room 
temperature (X) and oxidised using 0.5 eq. 4-PDS (XVII). The peptide was not fully StBu 
deprotected and once more two disulphides were formed. Therefore, it was considered that 
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the formation of two disulphides occurs in solution following test cleavage because of both 
StBu deprotected cysteines being activated by 4-PDS. To investigate this, the disulphides 
were reduced with 1 eq. DTT in 10 NMP overnight which reduced the disulphides but did 
not affect the remaining StBu protection groups. A small amount of resin was reacted with 
a small amount of iodoacetamide in 100:1 NMP:DIPEA for 10 min at 38°C and 
subsequently the peptide was test cleaved. In contrast to the previously performed 
maleimide reaction, alkylated cysteines were observed in this reaction. Since only two 
alkylated cysteines were observed it was concluded that the Mmt groups were unaffected 
and that the formation of the two disulphides must occur during the test cleavage when 
Mmt is deprotected. This also explained the formation of two disulphides in peptide 1r, 
which were not because of Trt being deprotected as initially thought. 
A new synthesis was made (peptide 1v) and StBu deprotected using 
mercaptoethanol at room temperature (X). The deprotected cysteines were oxidised using 
DMSO in NMP (XVIII). Mmt was deprotected using 1% TFA with shorter reaction time 
to reduce the possible cleavage from the resin (XI). Complete Mmt deprotection was 
confirmed by reaction with iodoacetamide, but the DMSO oxidation (XVIII) was not able 
to form the second disulphide. Prolonged DMSO oxidation and oxidation in neat DMSO 
was pursued, but it did not form the second disulphide. A small amount of bis-disulphide 
peptide was observed when the peptide was oxidised with less than 0.1 eq. of 4-PDS, but it 
is possible that the second disulphide is formed in solution following the test cleavage. 
 
2.5.4 Fourth orthogonal strategy 
Since it was considered to be too difficult to form the second disulphide on resin, and most 
likely even more difficult to form the third, the initial strategy was pursued once more after 
it had been shown to be possible to deprotect StBu and form the first disulphide on resin. 
 Peptide 1w was StBu deprotected (X) and oxidised on resin (VII). The 
oxidation was done twice before the peptide was fully oxidised. The peptide was also 
successfully oxidised using 1 eq. 4-PDS. However, formation of two disulphides was 
observed in another attempt with 1 eq. 4-PDS. The DMSO oxidised mono-disulphide 
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peptide was cleaved from the resin and purified in 7% yield. Consequently, the yield was 
greatly increased compared to the mono-oxidised peptide 1o. Since no problems were 
observed in the second oxidation of peptide 1o using 10 eq. of 4-PDS (XIII) a test 
oxidation was made with peptide 1w using the same conditions. The second disulphide was 
formed already after two hours and consequently the remaining peptide was oxidised using 
these conditions (XIX). The yield of the second oxidation and purification was 69.2%. The 
final disulphide was formed by iodine oxidation (XX) and the peptide was purified. The 
yield of the final oxidation and purification was 11.4% and the overall yield of the 
orthogonal synthesis was 0.55%. An overview of the orthogonal oxidation is depicted in 
Figure 2.9 where the observed MW of the intermediary products is shown. 
 
 
Figure 2.9. An overview of the orthogonal oxidation. The m/z peak of the quadruple charged peptide is 
shown with the total intensity count from the mass spectrometer below. On top is shown the expected MW 
and the retention time on the HPLC-MS. The gradient was 5-95% acetonitrile containing 0.1% formic acid 
against 0.1% formic acid in water over 20 min. From left to right are the reduced peptide with two Acm 
protection groups and two StBu protection groups, the StBu deprotected peptide, the mono-oxidised peptide, 
the bis-oxidised peptide and the tris-oxidised peptide (1w). The error between the expected and observed 
MW in three cases was caused by an inaccuracy in the calibration of the mass spectrometer. 
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2.5.5 Orthogonal synthesis of a non-native gurmarin disulphide isomer 
Since the thermolysin cleavage of the redox buffer oxidised gurmarin (peptide 1e) showed 
two possible disulphide connectivities, the possible non-native Cys3-17, Cys10-23, Cys18-
33 gurmarin disulphide isomer (9) was synthesised using the orthogonal oxidation strategy. 
In general, the yields of the synthesis steps were comparable and the overall yield was 
0.34%. However, an inseparable +109 Da by-product from the iodine oxidation was 
present in the final isolated gurmarin isomer. 
 
2.5.6 UPLC co-injection of gurmarin and gurmarin isomer 
To investigate whether the redox buffer oxidised gurmarin (peptide 1e) was identical with 
the orthogonally oxidised gurmarin (peptide 1w) or the gurmarin isomer 9, peptide 1e was 
co-injected on UPLC with the two orthogonally oxidised peptides (see Figure 2.10). One 
peak was observed when peptide 1e and 1w were co-injected, while two peaks were 
observed when peptide 1e and 9 were co-injected. This confirms the native disulphide 
connectivity of peptide 1e. The broader peak of the gurmarin isomer 9 was caused by the 
by-product described above. 
 
 
Figure 2.10. Co-injection of peptide 1e 
and 1w (top) and peptide 1e and the 
gurmarin disulphide isomer 9 (below). 
The gradient is 5-95% of acetonitrile 
containing 0.05% TFA against 0.05% 
TFA in water over 16 min. The retention 
times are indicated next to the peaks. 
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 A paper describing the work with the random oxidation of gurmarin, 
thermolysin cleavage, orthogonal oxidation of gurmarin and the gurmarin isomer along 
with the confirmation by co-injection on UPLC was accepted for publication (see 
Appendix D). 
 
2.6 DISCUSSION 
In this chapter, different synthesis strategies of gurmarin and work on structure 
confirmation were described. 
 In the first strategy pursued, gurmarin was oxidised using a partial orthogonal 
strategy. The first disulphide was formed selectively using Trt protection of the cysteine 
pair followed by air oxidation and the final two disulphides were oxidised concurrently by 
iodine oxidation of Acm protected cysteines. The three possible combinations of this 
strategy were pursued, but in all cases non-native gurmarin disulphide isomers were 
obtained as confirmed by thermolysin cleavage. In the combination where the Cys3-18 was 
formed selectively (peptide 1d), the other native disulphides; Cys10-23 and Cys17-33 were 
also observed. Consequently, a small amount of native gurmarin was synthesised with this 
strategy. It was not possible to isolate the native gurmarin from the synthesis though, and it 
appeared that the iodine oxidation of Acm-protected cysteines formed disulphides between 
cysteines that were in close proximity in the linear sequence of gurmarin. A similar 
observation has previously been observed in a random 4-PDS oxidation of an ICK peptide 
[58]. Therefore, the selective formation of the first disulphide did not induce the formation 
of native disulphides in the final oxidation. 
 In the second oxidation strategy, gurmarin was oxidised randomly using a 
redox buffer containing GSH and cystamine. In an optimised buffer, gurmarin (peptide 1e) 
was synthesised in an overall yield of 14.1%. The yield of the oxidation and purification 
was 57.1%. In two previously reported random oxidations of gurmarin the yields were 
0.7% and 2.4% [9,41]. Consequently, the yield was significantly increased compared to 
these results. The major improvement compared to these results was the yield of the 
reduced gurmarin. This could partly be because of the reduction of aspartimide formation 
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by addition of HOBt in the piperidine used for Fmoc-deprotection which was not 
mentioned in the two cases. It could also be caused by generally improved synthesis and 
purification yields. The oxidation buffer used in this strategy also appeared to be superior 
to the ones published, since both yield and progress of the oxidation was improved in this 
work. 
 The six cysteines in gurmarin can be connected in 15 possible disulphide 
combinations. To investigate the disulphide connectivity of peptide 1e, a partial cysteine 
reduction and cyanylation assay [63] was made. Unfortunately, it was difficult to separate 
the cyanylated peptides and the concentrations and amounts obtained were very low. This 
complicated the MS analysis and made the assay very laborious. Two native disulphides 
were found using this method, but one non-native disulphide was found as well making 
these results inconclusive. It is possible that lyophilisation of the peptide fractions could 
have improved the MS analysis. However, it would also have made the assay more 
laborious and would not affect the low purity and the amount of peptide in the fractions. 
Another possibility would have been to do the other assay described in chapter 1.2.2 [64] in 
which aminoethylation of reduced cysteines elegantly introduces trypsin cleavage sites in 
the peptide. The aminoethylation is preceded by a similar partial reduction and alkylation as 
done in this work though. Therefore, it is likely that similar complications with separation 
of the reduced and alkylated peptides would be observed in this assay as well. 
 Consequently, a different attempt was made to investigate the connectivity of 
the disulphides. A thermolysin cleavage of peptide 1e produced only two disulphide-
containing fragments; one fragment with Cys10-23 (8) and one fragment with either the 
native Cys3-18, Cys17-33 connectivity (6) or the non-native Cys3-17, Cys18-33 connectivity 
(7). To investigate which of the fragments 6 or 7 that was obtained in the thermolysin 
cleavage of peptide 1e, the two fragments were synthesised. It was not possible to 
distinguish between these two fragments though and as a result thereof the thermolysin 
cleavage was not able to confirm the disulphide connectivity of peptide 1e. Nonetheless, it 
was possible to rule out 13 of the 15 possible disulphide combinations. The pH in the 
thermolysin cleavage was 6.5 and disulphide scrambling was therefore a possibility. 
However, if scrambling had occurred, it would be anticipated that multiple disulphide-
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containing fragments had been observed. Since this was not the case, the occurrence of 
disulphide scrambling in the thermolysin cleavage was ruled out. 
 A third synthesis strategy was attempted. This was a fully orthogonal 
oxidation of gurmarin, which ensured that the native disulphide connectivity would be 
obtained. A number of resins, protection groups, positions and order of protection groups, 
deprotection methods and oxidation methods were pursued. Initially, StBu was deprotected 
using mercaptoethanol and air oxidised on resin but the deprotection was not reproducible. 
Subsequently, Mmt was used for protection of the first cysteine pair but it appeared that 
the deprotection of Mmt also deprotected Trt, since a 4-PDS oxidation of the Mmt 
deprotected peptide produced two disulphides. Later it was shown that on-resin oxidation 
using 4-PDS in many cases formed two disulphides because both reduced cysteines were 
activated by 4-PDS. After test cleavage of the peptide, the activated cysteines reacted with 
cysteines that were Trt-deprotected during the TFA treatment used in the test cleavage. 
This phenomenon was confirmed using iodoacetamide alkylation, but at the time of the 
Mmt deprotections only unsuccessful cysteine alkylation with 3-maleimidopropionic acid 
had been made. 
 Mercaptoethanol deprotection of StBu was reintroduced with a changed 
batch, but there were still some problems with reproducibility of both deprotection and 
oxidation. In some cases it was possible to oxidise on-resin using 4-PDS and in some cases 
both cysteines reacted with 4-PDS even though the same conditions were used. It was 
speculated that it could be due to use of different resin batches and possibly inaccuracy in 
the determination of the loading of the resin. This was not tested due to lack of time 
though. Using StBu, Mmt and Acm protection of the cysteines three on-resin disulphide 
formations were attempted, but it was not possible to form the second disulphide using 
DMSO or 4-PDS for oxidation. Finally, the orthogonal oxidation of gurmarin succeeded 
with peptide 1w using StBu protection to form the first disulphide on resin, followed by 
stepwise oxidation in solution of Trt and Acm protected cysteines. The overall yield of the 
synthesis was 0.55% and consequently much lower that the random oxidation of peptide 
1e. But whereas the random oxidation has 15 possible disulphide combinations, the 
orthogonal oxidation strategy produces only the wanted disulphide combination. In 
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another published orthogonal synthesis of an ICK peptide, the overall yield was not 
provided [58]. In general, the yields of the single steps appeared comparable though, but 
the synthesis route in this work has the advantage of on-resin disulphide formation and 
oxidation directly in fractions from preparative HPLC purification. This reduces the 
handling steps and makes this synthesis route less laborious. It could be possible to use 
Mmt instead of StBu and still form the first disulphide on resin using DMSO. Since the 
formation of two disulphides when Mmt protection was used in the first step was caused 
by 4-PDS and not because Trt protection groups were affected by the Mmt-deprotection 
the DMSO oxidation would most likely be similar in the two cases. This would have 
further reduced the laboriousness of the orthogonal oxidation of gurmarin.  
 The orthogonal synthesis route was used to synthesise the non-native 
gurmarin disulphide isomer (9) which the thermolysin cleavage indicated as a possible 
product of the random oxidation of peptide 1e. A co-injection on UPLC of peptide 9 and 
peptide 1e showed a separation of the two peptides, while only one peak was observed 
when peptide 1e and peptide 1w were co-injected. Previously, partial orthogonal synthesis 
strategies have been used to confirm disulphide connectivity of cystine knotted peptides 
[59,60]. However, this result is unique since a fully orthogonal synthetic approach is used to 
confirm the disulphide connectivity of a randomly redox buffer oxidised ICK peptide. 
 In the orthogonal synthesis of gurmarin another strategy could have been 
pursued. In a previously published report [57], a cystine knotted peptide was oxidised 
orthogonally using a one-pot strategy where the first cysteine pair was Trt-protected. This 
cysteine pair was deprotected concurrently with cleavage from the resin and oxidised in 
solution. The final two disulphide pairs are tert-butyl (tBu) protected and 4-methylbenzyl (4-
MBzl) protected. These two groups are both deprotected and oxidised using 4% DMSO in 
TFA, tBu selectively first and 4-MBzl subsequently by heating the solution to 60°C. 
However, it has been reported that low recovery of Trp-residues are observed after this 
treatment [122] and since two Trp-residues are present in gurmarin this oxidation method 
are not likely to be applicable to the synthesis of gurmarin. 
 Other cysteine protection groups, deprotection conditions and oxidation 
conditions were considered for the orthogonal strategy but not used due to lack of time or 
 Synthesis of gurmarin  
41 
due to initial results indicating difficulties. Cysteines protected by phenylacetamidomethyl 
can be oxidised using similar conditions as for oxidation of Acm-protected cysteines and in 
addition they are also oxidised by the enzyme penicillin aminohydrolase [123]. TCEP was 
also tried for deprotection of StBu, but no deprotection was observed. Instead of using 
iodine for oxidation of Acm-protected cysteines thallium(III)trifluoroacetate could have 
been used [124]. The iodine oxidation appeared to produce side products that were not 
separable as was the case in the orthogonal oxidation of the gurmarin isomer (9). The 
thallium(III)trifluoroacetate oxidation has also been reported to modify unprotected Trp-
residues [124] though, and consequently side products would also be expected for this 
reaction. 
 The three on-resin disulphide formation strategy did not succeed since it was 
not possible to form the second disulphide with DMSO or 4-PDS oxidation. However, 
only two different positions of the StBu and Mmt protection groups were tried. It is 
possible that by positioning one pair at the Cys3-18 residues the second on-resin oxidation 
could succeed. The possibility of forming the third disulphide on resin was not 
investigated. It is possible though, that the formation of the first two disulphides would 
position the final two cysteines in closer proximity, thereby inducing the formation of the 
last disulphide. However, it is also possible that protection groups of the other residues in 
the peptide makes the on-resin folding of the peptide impossible. 
 
2.6.1 Outlook 
The development of the stable redox oxidation strategy which provides high yields of 
gurmarin with the native ICK disulphide connectivity has the potential to be used both for 
the synthesis of grafted analogues of gurmarin, but also for other ICK peptides. In 
addition, the orthogonal synthesis strategy can be used for the synthesis of gurmarin, 
gurmarin analogues, other ICK peptides or gurmarin disulphide isomers. When combined 
with thermolysin cleavage, the orthogonal synthesis strategy can also be used to confirm 
disulphide connectivity of randomly oxidised ICK peptides. 
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2.7 EXPERIMENTAL PROCEDURES 
2.7.1 Solid Phase Peptide Synthesis 
Peptides were synthesised in 0.1 mmol scale on an Applied Biosystems (Carlsbad, CA) ABI 
433A Peptide Synthesizer using standard protocols; piperidine:NMP 20:80 was used for 
Fmoc deprotection and 4 eq. of amino acid:2-(1-H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU):HOBt, 8 eq. DIPEA in 
dimethylformamide (DMF):NMP 2:2.65 for coupling or a CEM Liberty Automated 
Microwave Peptide Synthesizer (Matthews, NC) using standard protocols; 0.05 M HOBt in 
5:95 piperidine:NMP for Fmoc deprotection and 6 eq. of amino acid:Oxyma Pure:1,3-
diisopropylcarbodiimide (DIC) in NMP for coupling. Standard couplings were 5 min at 
75°C. Gln was coupled twice while Cys and His residues were coupled twice at 50°C. 
Capping was done using acetic anhydride in NMP. Unless otherwise stated, the peptides 
were synthesised on a preloaded Gly-wang-PS LL resin. Gly-HMPB-Chemmatrix and Gly-
Wang-Chemmatrix were purchased at PCAS BioMatrix (St-Jean-sur-Richeliau, Canada). 
Gly-Wang-TentaGel was purchased at Iris Biotech GmbH (Marktredwitz, Germany). Gly-
Wang-PS LL resin, Gly-NovaSynTGT, Gly-2-ClTrt-PS and Fmoc-amino acids were 
purchased from Novabiochem (Darmstadt, Germany) and side chain protection groups 
used were tBu (Asp, Glu, Tyr), Trt (Asn, Gln, His) and Boc (Lys, Trp). Cysteines were 
protected by Acm, Trt, StBu or Mmt. Boc-pyroglutamic acid was purchased from 
SigmaAldrich (St. Louis, MO). 
 
2.7.2 Peptide cleavage and deprotection of cysteine protection groups 
Peptides were cleaved from the resin using 20 ml 92:4:2:2 TFA:ethanedithiol:TIPS:water 
for 3 hours. Cleaved peptides were precipitated using 200 ml of diethyl ether and filtered. 
Trt protected cysteines were deprotected concurrently with peptide cleavage from the resin. 
StBu and Mmt protection groups were deprotected as outlined in Table 2.4. 
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2.7.3 Oxidation of cysteine residues 
In the first oxidation strategy and the gurmarin fragment synthesis, Trt-deprotected 
cysteines were oxidised in solution by air oxidation in 0.1 M Tris-HCl pH 7.8, 2 vol% 
DMSO. Acm-protected cysteines were oxidised using 20 eq. of iodine in 1:4 
water:methanol. The iodine oxidations were stopped by quenching the iodine with ascorbic 
acid. In both oxidations the peptide concentration was 0.02 mM and the peptide was 
oxidised for 48 hours. In the fragment syntheses the iodine oxidation was quenched after 1 
hour. 
 In the second oxidation strategy, gurmarin was oxidised in solution using a 
redox buffer. In the first attempt, reduced gurmarin was oxidised for 48 hours in 0.01 mM 
concentration using 0.1 M Tris-HCl (pH 7.8), 1 mM EDTA, 2 mM GSH, 2 mM cystamine, 
35 vol% DMSO, 6 vol% 2-dodecyloxyethanol. Secondly, a buffer optimisation was made 
using the conditions outlined in Table 2.3. Finally, gurmarin was oxidised for 48 hours in 
0.02 mM concentrations using 0.1 M Tris-HCl (pH 7.8), 1 mM GSH, 1 mM cystamine. 
 In the orthogonal oxidation strategy, deprotected cysteines were oxidised 
either on resin or in solution as outlined in Table 2.5. Peptide concentrations are provided 
for the oxidations in solution. 
 
2.7.4 Enzymatic cleavage 
Peptide 1b was cleaved with chymotrypsin (SigmaAldrich) in 0.1 M Tris-HCl, 10 mM CaCl2 
(pH 7.8) 24 hours at room temperature. The peptide:enzyme ratio was 5:1 w/w, 0.1 mg 
peptide/ml. Peptides 1b-d were cleaved with thermolysin (SigmaAldrich) in 0.2 M 
ammonium acetate, 10 mM CaCl2 (pH 6.5) 24 hours at 50°C. The peptide:enzyme ratio was 
1:1 w/w, 0.1 mg peptide/ml. Peptide 1e and the gurmarin fragments (10-13) were cleaved 
with thermolysin using similar conditions, but the cleavage was quenched after 4 hours by 
adding 10 µl TFA to 200 µl of the cleavage solution. 
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2.7.5 Partial reduction and cyanylation assay 
In the partial reduction and cyanylation assay peptide 1e was incubated with 10 or 30 eq. of 
TCEP (SigmaAldrich) for 15, 30, 60, 90 or 120 min. Subsequently, the reduced cysteines 
were cyanylated using 40 eq. of CDAP (SigmaAldrich) over the amount of TCEP for 30 to 
180 min. Both reactions were made in 0.1 M sodium citrate buffer (pH 3) containing 6 M 
guanidinium chloride. The optimal conditions were found to be 30 eq. of TCEP for 30 min 
followed by 40 eq. (over TCEP) of CDAP for 30 min. The peptides were separated using 
20-30% acetonitrile against 0.1% TFA in water over 30 min on a Waters Alliance analytical 
HPLC system using a Symmetry300, C18, 5 µm, 3.9 x 150 mm column (Waters 
Corporation, Milford, MA). Fractions were collected manually and analysed by MS. 
Fractions containing mono-disulphide fragments were cleaved by adding 40% methylamine 
in water containing 3 M guanidinium chloride. The peptides were cleaved for 60 min and 
analysed by MS. 
 
2.7.6 Preparative HPLC purification 
Peptides were purified on a Waters Delta Prep 4000 using a Waters XBridge Prep C18 
OBD column, 5 µm, 30x150 mm. Mobile phases were 0.1% TFA in water (A) and 0.1% 
TFA in acetonitrile (B). Peptides 1b-d were purified using 15-35% B over 40 min, 20 
ml/min. Peptide 1e was purified using 22-32% B over 40 min, 20 ml/min. Peptide 1w was 
purified using 23-33% B and a ODDMS 120A, 5 μm, YMC 4x125 mm column (FeF 
Chemicals, Denmark), 5 ml/min. 
 
2.7.7 Analytical equipment 
The peptides were analysed using Waters Acquity UPLC systems. A sulphate buffered 
system using a BEH Shield RP18 1.7 μm, 2.1 x 150 mm column and a gradient of 20% A 
in 1 min followed by 20-60% A over 8 min (A: 70% acetonitrile, 30% water. B: 0.2M 
Na2SO4, 0.04M H3PO4, 10% acetonitrile in water, pH 3.5), flow: 0.35 ml/min was used for 
peptides 1b-d and for the aspartimide separation. A TFA system using a BEH130, 1.7 μm, 
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2.1 x 150 mm column and a gradient of 5-95% of 0.05% TFA in acetonitrile against 0.05 % 
TFA in water over 16 min, flow: 0.4 ml/min was used for peptide 1e, 1w and the gurmarin 
isomer 9. For the evaluation of the random oxidation a BEH C18, 1.7 μm, 2.1 x 50 mm 
column and a gradient of 5% of 0.05% TFA in acetonitrile in 0.5 min followed by 5-60% 
of 0.05% TFA in acetonitrile against 0.05% TFA in water for 3.5 min was used. The MW 
of the peptides was determined using an Agilent 6230 TOF LC/MS (Agilent Technologies, 
Santa Clara, CA). Peptide concentration was determined by Chemiluminescent Nitrogen 
Detection using an Antek 8060 CLND HPLC detector (PAC, Houston, TX) [125]. The 
analytical data of the peptides are summarised in Table 2.7. 
 
Table 2.7. Analytical data of the peptides. The numbers in brackets refers to the major product obtained 
using the synthesis procedure, as confirmed by enzymatic cleavage. 
Peptide UPLC system Retention time Purity Expected MWa Observed MWa 
1b (2) Sulphate 5.4 min 99% 1052.5 1052.5 
1c (3) Sulphate 5.3 min 87% 1052.5 1052.5 
1d (4) Sulphate 5.7 min 100% 1052.5 1052.5 
1e TFA 5.8 min 97% 1052.5 1052.5 
1w TFA 5.7 min 77% 1052.5 1052.5 
9 TFA 5.3 min 84% 1052.5 1052.6 
a the MW are the monoisotopic mass of the quadruple charged mass to charge spectrum.  
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3. MELANOCORTIN ANALOGUES OF GURMARIN 
3.1 INTRODUCTION 
In this chapter, the synthesis of melanocortin analogues of gurmarin will be described. The 
proposal of synthesising melanocortin analogues of gurmarin is based on the structural 
similarity between gurmarin and AgRP(87-120; C105A) as depicted in Figure 1.5. Since it 
has been shown that the melanocortin receptor antagonist AgRP(87-120; C105A) can be 
turned into an agonist by inserting the His-D-Phe-Arg-Trp pharmacophore instead of Arg-
Phe-Phe in the active loop of AgRP(87-120; C105A) [96], a similar substitution was 
pursued in gurmarin in hope of obtaining MCR agonists (Figure 1.6). 
The random redox buffer oxidation was used for the synthesis of these 
analogues, since the random oxidation in chapter 2 was shown to produce native gurmarin 
in high yield and purity. Therefore, it was anticipated that the disulphide knot of gurmarin 
would provide sufficient structural stability to retain the disulphide connectivity despite the 
amino acid substitutions. In chapter 1 it was described how several cases has shown that 
native ICK structures are obtained using random oxidation despite engineering of the 
peptides [31,33-36]. The binding of the analogues to the MC1R, MC3R, MC4R and MC5R 
were characterised by competition binding studies with radiolabeled NDP-α-MSH. The 
peptides were not evaluated for their binding to the MC2R, since ACTH is the only 
endogenous agonist able to bind to this receptor in contrast to the other MCRs [73]. An 
experimental section is found at the end of this chapter. 
  
3.2 DESIGN AND SYNTHESIS OF MELANOCORTIN ANALOGUES OF GURMARIN 
Six melanocortin analogues of gurmarin were designed and synthesised. The sequences of 
the analogues are listed in Table 3.1. The analogues 14 and 15 have the His-Phe-Arg-Trp 
pharmacophore (L-Phe and D-Phe respectively) inserted in position 27-30 in gurmarin. This 
position corresponds to the position of the melanocortin binding residues, Arg-Phe-Phe(-
Asn) in AgRP(87-120; C105A) based on the structural alignment in Figure 1.6. Analogues 
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16 and 17 are L-Phe and D-Phe analogues where the binding loop has been expanded one 
residue. Consequently, the Asp-residue in position 30 of gurmarin is placed in position 31 
on the C-terminal side of the melanocortin pharmacophore in 16 and 17. The expansion of 
the binding loop by one residue was also done in the engineering work described 
previously, which turned the melanocortin antagonist AgRP(87-120; C105A) into an 
agonist [96]. Finally, 18 and 19 are L-Phe and D-Phe analogues that have the 
pharmacophore shifted one position towards the C-terminal end compared to 14 and 15. 
Consequently, the pharmacophore in 18 and 19 is surrounded by Asn and Lys compared to 
Val and His in 14 and 15. 
 
Table 3.1. Sequence alignment of gurmarin and the synthesised melanocortin analogues. The His-Phe-Arg-
Trp pharmacophore is highlighted in bold. D-Phe is indicated by a lower case f. Disulphides are indicated 
with lines. The yields of reduced and oxidised peptide are shown. The yield of the oxidation is shown in 
brackets. 
Peptide Structure Yields (%) 
  Reduced Oxidised 
    
Gurmarin *EQCVK KDELC IPYYL DCCEP LECKK VNWWD HKCIG   
14 *EQCVK KDELC IPYYL DCCEP LECKK VHFRW HKCIG 2.2 0.6 (28.2) 
15 *EQCVK KDELC IPYYL DCCEP LECKK VHfRW HKCIG 5.2 3.5 (67.3) 
16 *EQCVK KDELC IPYYL DCCEP LECKK VHFRW DHKCI G 9.5 1.4 (14.7) 
17 *EQCVK KDELC IPYYL DCCEP LECKK VHfRW DHKCI G 5.0 1.2 (24.0) 
18 *EQCVK KDELC IPYYL DCCEP LECKK VNHFR WKCIG 6.1 1.6 (26.2) 
19 *EQCVK KDELC IPYYL DCCEP LECKK VNHfR WKCIG 3.9 0.8 (20.5) 
  1     6    11    16    21    26    31    36      
 
The analogues were synthesised similarly to peptide 1e as described in chapter 2.3 and 
oxidised using the optimised redox buffer containing 1 mM GSH and 1 mM cystamine to 
facilitate the folding of the peptides. The oxidation of the analogues is illustrated in Figure 
3.1. Samples taken directly after addition of the redox buffer were shown by MS to be fully 
oxidised immediately. Multiple disulphide connectivities that are separable on UPLC were 
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Figure 3.1. Oxidation of the melanocortin analogues 14-19. From left to right are the chromatograms of the 
reduced peptide, the peptide directly after addition of redox buffer and the peptide after 48 hours of 
oxidation. Retention times are indicated next to the major peaks. The gradient is 20% A in 1 min followed by 
20-60% A against B over 8 min (A: 70% acetonitrile, 30% water. B: 0.2M Na2SO4, 0.04M H3PO4, 10% 
acetonitrile in water, pH 3.5). 
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present as illustrated in Figure 3.1. The retention times of the oxidised peptides are  
decreased compared to the reduced peptides as it was observed in the random oxidation of 
gurmarin (Figure 2.4). 
 
3.2.1 Design and synthesis of tetra-disulphide analogues of gurmarin 
Based on the structural alignment of gurmarin and AgRP(87-120; C105A) (Figure 1.5) it 
was attempted to design and synthesise gurmarin analogues containing a fourth disulphide 
surrounding the loop in which the melanocortin pharmacophore was grafted. The 
sequences of the synthesised analogues are shown in Table 3.2. The disulphide connectivity 
of the analogues are supposed to be Cys(1-4), Cys(2-5), Cys(3-8) and Cys(6-7) as in 
AgRP(87-120; C105A) with the cysteines numbered from the position from the N-terminal 
end. Consequently, the first three disulphides form the ICK, while the fourth disulphide is 
surrounding the grafting loop. 
 
Table 3.2. Sequence alignment of gurmarin, AgRP(87-120; C105A) and the synthesised tetra-disulphide 
analogues 20 and 21. Amino acids not native to gurmarin are highlighted in bold. D-Phe is indicated by a 
lower case f. The disulphides in 20 and 21 are indicated with lines. The numbering on top refers to AgRP(87-
120; C105A), while the numbering in the bottom refers to gurmarin and the analogues. The yields of reduced 
and oxidised peptide are shown. The yield of the oxidation is shown in brackets. 
Peptide Structure Yields (%) 
 Reduced Oxidised 
    1   4     9    14    19    24    29    34   
AgRP(87-120;C105A)       CVR LHESC LGQQV PCCDP AATCY CRFFN AFCYC R   
Gurmarin *EQCVK KDELC IPYYL DCCEP LECKK VNWWD HKCIG   
    
20 *EQCVK KDELC IPYYL DCCEP LECYC VNWWD HKCYC IG 13.4 8.5 (63.5) 
21 *EQCVK KDELC IPYYL DCCEP LECYC HfRWN AFCYC IG 12.9 0.78 (6.0) 
  1     6    11    16    21    26    31    36       
 
In analogue 20 two Cys-Tyr-Cys fragments present in AgRP(87-120; C105A) 
were inserted in gurmarin and the C-terminal Ile-Gly residues were preserved thereby 
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expanding the peptide with two residues. This analogue was designed to investigate the 
possibility of synthesising tetra-disulphide analogues of gurmarin. In analogue 21, the two 
Cys-Tyr-Cys fragments were inserted similarly to 20. In addition, the residues from the 
binding loop of the engineered agonist analogue of AgRP(87-120; C105A) [96] were 
inserted in hope of obtaining similar binding to the MCRs. Consequently, analogue 21 is a 
chimeric peptide containing parts from gurmarin, AgRP(87-120; C105A) and NDP-α-
MSH. 
The two tetra-disulphide analogues were synthesised and oxidised similarly to 
the other melanocortin analogues. In contrast to the oxidation of gurmarin and the first 
gurmarin analogues, the UPLC evaluation of the tetra-disulphide oxidation was more 
complicated. Because of the removal of Lys 24 and 25 in gurmarin the pI of the tetra-
disulphide analogues was lower than gurmarin and the other analogues. The lower pI was 
considered to cause the peptides to precipitate when the oxidation was quenched with TFA 
in the samples before evaluation by UPLC. Unfortunately, this was not discovered until 
after the oxidation and consequently the progress of the oxidation was not monitored for 
the tetra-disulphide analogues. Nonetheless, as can be seen in Figure 3.2 one peak was 
observed on UPLC after purification of oxidised 20 and 21. This indicates that only one 
product is formed in the oxidation of the tetra-disulphide gurmarin analogues like in the 
previous random oxidations.  
The synthesis of 20 was also attempted with Acm-protection of the cysteines 
forming the extra disulphide. In this synthesis route, it was intended to form the ICK in the 
redox buffer oxidation and subsequently form the fourth disulphide using iodine oxidation 
of the Acm-protected cysteines. It was not possible to isolate the random oxidised Acm-
protected peptide though, and since only one product was formed in the random oxidation 
of all four disulphides, this alternative synthesis route was dropped.  
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Figure 3.2. UPLC chromatograms after purification of reduced (top) and oxidised (below) 20 (left) and 21 
(right). Retention times are indicated next to the peaks. The gradient is 5-95% of 0.05% TFA in acetonitrile 
against 0.05% TFA in water over 16 min. 
 
3.2.2 Thermolysin cleavage of tetra-disulphide analogue 
To investigate the disulphide connectivity of the tetra-disulphide analogues a thermolysin 
digestion of 20 was made. Besides being native to AgRP the two inserted Cys-Tyr-Cys 
fragments provided extra thermolysin cleavage sites. Therefore, a fragment containing the 
extra inserted disulphide would be produced after thermolysin cleavage. The cleavage 
conditions were similar to those described in chapter 2. However, the cleavage was 
continued for 48 hours before the fragments were observed. The fragments obtained in the 
thermolysin cleavage are depicted in Figure 3.3. 
 The thermolysin cleavage indicated two possible disulphide combinations 
similarly to what was observed in the thermolysin cleavage of randomly oxidised gurmarin 
(1e). It was shown in chapter 2 that 1e in fact had the native disulphide connectivity. Due to 
that finding and based on the design of the peptide from the structural alignment, it was 
anticipated that the disulphide connectivity of 20 is the expected one as illustrated in Figure 
3.3 and not the other possible connectivity. However, no final evidence was found of the 
disulphide connectivity of 20. 
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Figure 3.3. HPLC-MS analysis of the thermolysin cleavage of 20. The chromatogram and the mass spectra 
of the highlighted peaks are shown on top. In the table below the expected fragments from the cleavage are 
listed. The bis-disulphide fragment (23) could also have the non-native Cys3-17, Cys18-35 disulphide 
connectivity. The asterisk indicates an N-terminal pyroglutamic acid. 
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Table 3.3. Binding affinity to the MCRs indicated by average pKi  ± S.E.M. and number of assays performed 
in brackets. Transformed Ki values are indicated in brackets below each pKi value. 
Peptide MC1R 
pKi (n) 
(Ki/[nM]) 
MC3R 
pKi (n) 
(Ki/[nM]) 
MC4R 
pKi (n) 
(Ki/[nM]) 
MC5R 
pKi (n) 
(Ki/[nM]) 
Gurmarin (1e) 
 
n.a. (4) n.a. (4)  5.38 ± 0.15 (3) 
(4,200) 
n.a. (4) 
14 5.05 ± 0.12 (3) 
(8,800) 
n.a. (3) 6.14 ± 0.01 (2) 
(720) 
n.a. (3) 
15 5.66 ± 0.11 (2) 
(2,200) 
n.a. (2) 5.47 ± 0.12 (2) 
(3,400) 
n.a. (2) 
16 n.a. (3) n.a. (3) 5.54 ± 0.18 (3) 
(2,900) 
n.a. (3) 
17 6.48 ± 0.02 (3) 
(330) 
5.41 ± 0.07 (3) 
(3900) 
6.06 ± 0.26 (3) 
(880) 
5.20 ± 0.05 (3) 
(6,300) 
18 n.a. (3) n.a. (3) 5.34 ± 0.01 (2) 
(4,600) 
n.a. (3) 
19 n.a. (3) n.a. (3) 5.72 ± 0.19 (4) 
(1,900) 
n.a. (3) 
21 - - 6.30 ± 0.21 (4) 
(500) 
- 
α-MSH 9.16 ± 0.05 (3) 
(0.69) 
7.51 ± 0.04 (4) 
(31) 
7.41 ± 0.26 (4) 
(39) 
6.75 ± 0.16 (3) 
(180) 
n.a. no activity; indicates that the binding affinity was above 10,000 nM. A dash indicates that no experiments 
were performed. 
 
3.3 MELANOCORTIN RECEPTOR BINDING ASSAYS 
The six melanocortin analogues of gurmarin (14-19) along with the tetra-disulphide 
melanocortin analogue of gurmarin (21), gurmarin (1e) and α-MSH as a reference were 
characterised for their ability to bind to the MC1R, MC3R, MC4R and MC5R. A summary 
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of the binding data is presented in Table 3.3. Gurmarin was not able to bind to the MC1R, 
MC3R and MC5R but it bound with low affinity to the MC4R. All synthesised analogues 
were able to bind to the MC4R. The most potent was the tetra-disulphide analogue (21) 
that had a binding affinity of 500 nM. This is around ten-fold lower affinity than the 
endogenous agonist α-MSH, which has low nM binding affinity for the four MCRs 
evaluated. Since 21 was synthesised at a late stage in the project, its binding to the other 
MCRs was not determined. Analogue 14 was the second most potent analogue in the 
binding assays with a binding affinity of 720 nM. It was more than ten-fold selective for the 
MC4R over the MC1R and did not bind to the MC3R and MC5R. Analogue 17 was the 
only analogue that bound to all the MCRs and also the only that bound to the MC3R and 
MC5R.  
 
 
Figure 3.4. An average of normalised binding curves from the most potent analogues on the MCRs. NDP-α-
MSH is included as reference (black line). Gurmarin (1e) (red line), 14 (blue line), 15 (purple line), 17 (green 
line), 19 (orange line).  
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In Figure 3.4 is shown a summary of the curves from the binding assays of 
the most potent peptides on each receptor. 
 
3.4 DISCUSSION 
In this chapter, the design, synthesis and functional characterisation of melanocortin 
analogues of gurmarin were described. 
 The analogues were designed based on structural alignment of AgRP(87-120; 
C105A) and gurmarin, and oxidised using the random redox buffer conditions optimised 
for the synthesis of gurmarin as described in chapter 2. The disulphide connectivity was 
not determined for the analogues, but in all analogue oxidations one peak was observed 
after 48 hours of oxidation (Figure 3.1). This indicates the formation of the 
thermodynamically most favourable conformation, which in the case of gurmarin was 
shown in chapter 2 to have the native ICK disulphide connectivity. Similarly to the 
oxidation of gurmarin, all peptide is oxidised immediately after addition of the redox 
buffer. The UPLC analysis of the oxidation indicates that it is possible to separate the 
multiple differently disulphide connected species. Because of only one peak being observed 
and because of the separability of the differently disulphide connected peptides, it was 
anticipated that the ICK was produced in the oxidation of the melanocortin analogues.  
 Two tetra-disulphide analogues of gurmarin were designed and synthesised 
by insertion of two Cys-Tyr-Cys sequences from AgRP(87-120; C105A) in gurmarin based 
on the structural alignment of the two peptides. In the first analogue 20, only these two 
sequences were inserted, while the entire active loop from an engineered agonist analogue 
of AgRP(87-120; C105A) [96] was inserted into the second analogue 21. In both peptides, 
one peak was observed on UPLC after preparative HPLC indicating the formation of one 
major product as it was the case with the first synthesised melanocortin analogues. To 
investigate the disulphide connectivity of 20 the peptide was cleaved with thermolysin 
similarly to the cleavage of random oxidised gurmarin (1e) described in chapter 2. The 
cleavage had to be continued for 48 hours before fragments of 20 were observed, which 
indicates that the tetra-disulphide analogues have higher proteolytic stability than gurmarin. 
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All disulphide containing fragments observed was expected to be found based on the 
disulphide connectivity in the design of the peptide. This indicated that the expected tetra-
disulphide peptide in fact was formed in the redox buffer oxidation. Nonetheless, it is 
possible that the bis-disulphide fragment (23) observed could have the non-native Cys3-17, 
Cys18-35 disulphide connectivity. A similar fragment was observed in the thermolysin 
cleavage of redox buffer oxidised gurmarin (1e) as shown in chapter 2. Since it was proven 
that the native disulphide connectivity was produced in the gurmarin oxidation, it was 
assumed that this was also the case for 20, despite no complete evidence was established.  
The yields of the melanocortin analogues of gurmarin were lower than in the 
synthesis of gurmarin. This is expected to be caused by the synthesis of the reduced 
gurmarin being optimised more compared to the synthesis of the analogues. In addition, 
the amino acid substitutions made in the analogues could affect the yield of the oxidation 
negatively. In general, the yields of the analogues were comparable. In two cases, 15 and 20 
the oxidation yields were very high. In contrast, the oxidation yield of 21 was very low. No 
explanation was found to this observation, since everything was done similarly and nothing 
unusual was observed during the oxidation or purification. Only, the complications when 
evaluating the oxidation of the tetra-disulphide analogues by UPLC were observed. 
However, since one of these oxidations gave a high yield, while the other gave a low yield, 
this is not likely to have caused the observed difference in the oxidation. 
 The analogues 14-19, 21 and gurmarin (1e) were characterised for their 
binding to the MCRs. Gurmarin were able to bind with low affinity to the MC4R. This is 
surprising, since gurmarin does not contain the melanocortin pharmacophore. All 
melanocortin analogues of gurmarin were also able to bind to the MC4R, however no 
peptide had had similar binding affinity as the endogenous agonist α-MSH. The tetra-
disulphide analogue 21 had the highest affinity with a Ki of 500 nM, but was not evaluated 
at the other MCRs. Since the entire binding loop was replaced with the corresponding loop 
from the engineered AgRP agonist that had low nM actitivy on the MC4R [96], a higher 
binding affinity was expected for 21. It is possible though, that 21 would be more potent 
for activation of the MC4R. Only EC50 values describing activation of the MCRs were 
determined for the reported engineered AgRP agonist, while only Ki values describing 
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binding to the MCRs were determined for the analogues synthesised in this work. 
Analogue 14 had the second highest affinity for the MC4R, a Ki of 720 nM and was more 
than ten-fold selective for the MC4R over the MC1R. The binding to the MC3R and 
MC5R could not be determined since they were higher than 10,000 nM. Analogue 17 was 
the only analogue that was able to bind to all MCRs. It bound with around three-fold 
higher affinity to the MC1R than the MC4R and around ten- and twenty-fold higher 
affinity to the MC1R compared to the MC3R and MC5R respectively. Analogue 15, one of 
the D-Phe analogues like 17 bound with slightly higher affinity to the MC1R than the 
MC4R. Finally, analogues 16, 18 and 19 only bound to the MC4R and 18 was the only 
analogue that did not show improved binding to the MC4R compared to gurmarin. 
 The binding experiments of the melanocortin analogues confirmed the 
hypothesis that it was possible to synthesise analogues of gurmarin which bound to the 
MCRs. The difference observed in binding affinities of these highly similar analogues are 
affected by four factors; the position of the pharmacophore in the loop, the size of the 
loop, the residues adjacent to the pharmacophore and whether the phenylalanine residue in 
the pharmacophore is in D or L conformation.  
In the least potent analogues 18 and 19, the pharmacophore was shifted one 
position towards the C-terminal. Consequently, this seems to be a less favourable position 
in the loop, but it could also be due to different residues being adjacent to the 
pharmacophore. In 18 and 19 Asn and Lys are adjacent, in 14 and 15 Val and His are 
adjacent, in 16 and 17 Val and Asp are adjacent and in 21 Cys and Asn are adjacent. As 
shown in Figure 1.4b, the pharmacophore of the three MSH peptides are surrounded by 
either Glu or Gly on the N-terminal and Gly or Asp on the C-terminal. A comparison with 
the natural melanocortin agonists thereby indicates that the positively charged Lys residue 
on the C-terminal side of the pharmacophore in 18 and 19 could affect the binding to the 
MCRs negatively. A Lys residue is also present on the C-terminal side of the subnanomolar 
agonist MT-II [92] though. However, in MT-II the positive charge in the side chain of the 
Lys residue is removed by an amide bond formation with an Asp side chain on the N-
terminal side of the pharmacophore. On the other hand 17, the only analogue with activity 
on all MCRs, has an Asp residue on the C-terminal side of the pharmacophore like γ-MSH. 
 Discussion 
  58 
It is possible that this improves the binding compared to the other analogues, but it is not 
known to what extent. In another report, several analogues were made with both positively 
charged, negatively charged, hydrophobic and short side chains on the N-terminal side of 
the pharmacophore [126]. These changes only affected the binding to the MC5R, which 
indicates that the residue on the N-terminal side of the pharmacophore only has a minor 
effect on MCR binding. 
 It has previously been shown that loop sizes of cyclised melanocortin 
analogues can affect MCR selectivity. In one example, a peptide was reversed from an 
agonist to an antagonist by increasing the ring one carbon atom [127]. In another example, 
various modifications of ring sizes affected MCR affinity and selectivity [126]. This means 
that the increased loop in 16 and 17 might have a significant effect on both binding and 
selectivity. 
 Finally, the higher binding affinity for the MC1R for the D-Phe analogues 15 
and 17 compared with their respective L-Phe analogues 14 and 16 indicates that the D-Phe 
substitution has highest effect on the MC1R. On the MC4R, the d-Phe analogues 17 and 19 
has higher binding affinity than their respective L-Phe analogues 16 and 18 while the 
opposite is the case for 14 and 15 where the L-Phe analogue 14 has the highest affinity. In 
previously reported studies it appears the D-Phe substitutions affect the binding to the 
MC1R to a lower extent than the other MCRs in contrast to what was observed in this 
work [128-130]. However, in most studies found on the development of melanocortin 
analogues only D-Phe analogues were evaluated. This means that it is hard to make a 
general conclusion on how the D-Phe substitution affects MCR selectivity. In addition, this 
novel incorporation of the melanocortin pharmacophore in an ICK framework could very 
well behave differently compared to usual short linear or side chain cyclised melanocortin 
analogues. 
 
3.4.1 Outlook 
The work described in this chapter demonstrated the possibility of turning unrelated 
peptides into melanocortin receptor analogues. Since only binding assays on the MCRs 
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were performed and no functional assays, it is not known whether the synthesised peptides 
are agonists, partial agonists or antagonists. It would have been interesting to elucidate this, 
but the time and resources did not allow for this. In addition, further investigation of which 
position in the loop that favours binding to the MCRs most could have been made. For 
example by synthesising analogues with the pharmacophore at various positions, but 
surrounded by identical residues. This could be two Gly residues since these are native to 
the MSH peptides and their lack of side chains would rule out the possible effect of side 
chain interactions from the residues adjacent to the pharmacophore. In general, additional 
engineering of the structures could have produced even more potent and selective 
compounds. 
 Interestingly, it was possible to design and synthesise tetra-disulphide 
analogues of gurmarin based on structural alignment with AgRP(87-120; C105A), which 
appeared to have the expected disulphide connectivity. These analogues could provide the 
basis for a novel approach in the design of melanocortin analogues for obesity treatment. 
Other engineering work on ICK peptides and cyclotides has indicated the possibility for 
oral bioavailability [29,35,131]. Additional exploration of this opportunity for the peptides 
synthesised in this work should be investigated before anything can be concluded. 
Nonetheless, oral treatment of obesity is a highly valuable concept with the emerging 
worldwide prevalence of obesity [132] and the current deficiency in treatment options 
[133]. 
 
3.5 EXPERIMENTAL PROCEDURES 
3.5.1 Synthesis of melanocortin analogues of gurmarin 
The peptides were synthesised on a CEM Liberty as described for the synthesis of 
gurmarin in chapter 2.7 using similar side chain protection groups. Arginine was protected 
with 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf). All cysteines were Trt 
protected, except for Cys25 and Cys33 which were Acm protected only in the alternative 
synthesis attempt of 20. The peptides were oxidised using the redox buffer described in 
chapter 2.7. The peptide peptides were purified using the preparative HPLC system 
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described in chapter 2.7. 14 was purified using 10-30% B, 15 using 8-28% B, 16-19 using 
20-30% B, 20 using 27-37% B and 21 using 23-43% B. The analytical data of the 
melanocortin analogues are summarised in Table 3.4. The analytical equipment used were 
the same as described in chapter 2.7. 
 
Table 3.4. Analytical data of the melanocortin analogues of gurmarin. 
Peptide UPLC system Retention time Purity Expected MWa Observed MWa 
14 TFA 4.7 min 81% 1058.7 1058.8 
15 TFA 4.7 min 89% 1058.7 1058.8 
16 TFA 5.1 min 83% 1087.5 1087.5 
17 TFA 5.0 min 91% 1087.5 1087.5 
18 TFA 4.9 min 83% 1053.0 1053.0 
19 TFA 4.7 min 83% 1053.0 1053.0 
20 TFA 5.8 min 93% 1121.0 1121.0 
21 TFA 6.3 min 99% 1119.2 1119.2 
a the MW are the monoisotopic mass of the quadruple charged mass to charge spectrum.  
 
3.5.2 Enzymatic cleavage 
Peptide 20 was cleaved with thermolysin using the same conditions as described in chapter 
2.7. The cleavage was continued for 48 hours. 
 
3.5.3 Melanocortin receptor assays 
The binding assays for the MCRs were performed by Novo Nordisk laboratory technicians 
as described previously [134] and each binding assay was performed in duplicate. Baby 
Hamster Kidney cells stably expressing the different MCRs were generated by transfection 
with an expression vector. The synthesised peptides were evaluated by incubation with 
homogenised membranes expressing the MCRs and a radiolabeled 125I-NDP-α-MSH 
(Perkin-Elmer, Waltham, MA) using a filtration system to separate bound radioligand from 
unbound. The peptides were initially dissolved in DMSO to a concentration of 4 mM and 
the peptides were evaluated in a range from 10 pM to 10 µM. 
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 MC1R assay: The assay was performed in a total volume of 250 µL with 100 
pM 125I-NDP-α-MSH, test peptide and 200 µL cell membrane (35 µg/mL) added. The 
compounds were diluted in 25 mM HEPES pH 7.4, 0.1 mM CaCl2, 1 mM MgSO4, 1 mM 
EDTA, 0.1% ovalbumin, 0.005% Tween-20, 5% hydroxypropyl-β-cyclodextrin buffer. The 
samples were incubated in a microtiter plate for 90 min at 30°C. The incubation was 
stopped by filtration of the plate through a polyethyleneimine treated filter plate using a 
Packard Filtermate harvester (Packard Instrument Company, Meriden, CT). After filtration, 
the filters were washed 10 times with ice cold 0.9 % NaCl and dried at 50°C for 30 min. 
Finally, 30 µL of Microscint 0 (Packard Instrument Company, Meriden, CT) were added to 
each well and the plate was counted (1 min/well) in a Topcounter (Packard Instrument 
Company, Meriden, CT). 
 MC3R and MC5R assays: The assays were performed in a total volume of 
100 µL with 250 pM 125I-NDP-α-MSH, test peptide and 30 µL cell membrane (30 µg/mL) 
added. The compounds were diluted in 25 mM HEPES pH 7.4, 1 mM CaCl2, 5 mM 
MgSO4, 0.1% ovalbumin, 0.005% Tween-20, 5% hydroxypropyl-β-cyclodextrin buffer. The 
samples were incubated in a microtiter plate for 60 min at room temperature. The 
remaining procedure was performed similarly to the MC1R assay. 
 MC4R assay: The assay was performed in a total volume of 200 µL with 79 
pM 125I-NDP-α-MSH, test peptide and 50 µL cell membrane (150 µg/mL) added. The 
compounds were diluted in 25 mM HEPES pH 7.0, 1 mM CaCl2, 1 mM MgSO4, 1 mM 
ethylene glycol tetraacetic acid, 0.02% bacitracin, 0.1% ovalbumin, 0.005% Tween-20, 5% 
hydroxypropyl-β-cyclodextrin buffer. The samples were incubated in a filter plate for 120 
min at room temperature. The incubation was stopped by filtration of the plate using a 
Millipore vacuum manifold (Merck Millipore, Billerica, MA). After filtration, the filter was 
washed with 100 µL ice cold 0.9 % NaCl and air dried. Radioactivity retained on the filter 
was counted using a Cobra II auto γ-counter (Packard Instrument Company, Meriden, CT). 
 The data analyses from the receptor assays were performed using the 
program GraphPad Prism, GraphPad Software, USA. pIC50 values were calculated using a 
nonlinear regression model and pKi values were calculated from the pIC50 values using the 
Cheng−Prusoff equation Ki = IC50/[1 − L/Kd], where L is the concentration of the 
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radioligand, Kd is the dissociation constant of NDP-α-MSH calculated from saturation 
analysis and IC50 values are the concentration of test peptide when 50% of the radioligand 
is displaced.  
To determine Kd of the radioligand for the MCRs, a saturation analysis was 
performed. For the MC1R, 10 concentrations of 125I-NDP-α-MSH in the range of 0.1 pM 
to 100 pM were used, for the MC3R and the MC5R, 12 concentrations of 125I-NDP-α-
MSH in the range of 12.5 pM to 5 nM were used, and for the MC4R 11 concentrations of 
125I-NDP-α-MSH in the range of 2.6 pM to 800 pM were used. Nonspecific binding was 
determined in the presence of 10 μM 125I-NDP-α-MSH. Kd: MC1R 45 ± 12 pM (n = 3), 
MC3R 1.46 ± 0.34 nM (n = 3), MC4R 0.34 ± 0.13 nM (n = 5), and MC5R 0.96 ± 0.23 nM 
(n = 4). Kd values were calculated using the one site binding model (hyperbola) in 
GraphPad Prism.  
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4. MELANOCORTIN ANALOGUES OF KALATA B1 
4.1 INTRODUCTION 
This chapter will briefly introduce and discuss work that was conducted during a four 
month stay at Prof. David Craik’s lab at the Institute for Molecular Bioscience, The 
University of Queensland, Brisbane, Australia during this Ph.D. project. 
 The project proposal was to design and synthesise melanocortin analogues of 
the cyclotide kalata B1 by grafting the melanocortin pharmacophore into one of the inter-
cysteine loops. The analogues were characterised for their binding to the MC1R, MC3R, 
MC4R and MC5R and the analogue that bound with highest affinity to the MC4R was also 
evaluated for its ability to activate the MC4R. In addition, the ability to obtain the native 
kalata B1 cyclotide fold were investigated using NMR spectroscopy and a NMR derived 
structure of the most potent analogues were calculated. 
 A paper describing the work and results from the stay was submitted and can 
be found in Appendix E. Since all work and results are presented in the appendix, only the 
most important findings are repeated in this chapter. These will be discussed compared 
with the results obtained for the melanocortin analogues of gurmarin. 
 
4.2 DISCUSSION 
In contrast to the most MC4R potent melanocortin analogue of gurmarin (21), the most 
potent melanocortin analogue of kalata B1, kB1[GHFRWG;23-28] (25) bound with higher 
affinity to the MC4R than α-MSH. As the name of the peptide indicates, the melanocortin 
pharmacophore is surrounded by two Gly residues as discussed in chapter 3. A Gly residue 
is found adjacent to the N-terminal of the pharmacophore in γ-MSH, while Gly residues 
are found adjacent to the C-terminal of the pharmacophore in α-MSH and β-MSH. This 
could be one explanation to the improved binding observed in kB1[GHWRWG;23-28] 
compared to the gurmarin analogues. Similarly to the observation of the gurmarin 
analogues, a D-Phe substitution in the pharmacophore of kB1[GHFRWG;23-28] had most 
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effect on the MC1R, and decreased the binding around ten-fold at the MC4R. In addition, 
this analogue was the only analogue that bound to all four MCRs evaluated similarly to 17. 
 The most potent analogue in binding to the MC4R, kB1[GHFRWG;23-28] 
(25) was evaluated for its ability to activate the MC4R. Despite being more potent than α-
MSH in binding to the MC4R, it was more than ten-fold less potent in activating the 
MC4R. The D-Phe analogue of kB1[GHFRWG;23-28] had similar binding affinity to the 
MC4R as the tetra-disulphide gurmarin analogue 21. As discussed in chapter 3, the binding 
affinity of 21 to the MC4R was lower than expected compared to the engineered AgRP 
agonist [96]. It was suggested though, that the D-Phe substitution could make analogue 21 
more potent at activating the MC4R as observed previously in the discovery of NDP-α-
MSH [90]. Similarly, it is possible that the D-Phe analogue of kB1[GHWRWG;23-28] is 
more potent at activating the MC4R compared to kB1[GHFRWG;23-28] despite its lower 
binding affinity for the MC4R.  
 
4.2.1 Outlook 
The melanocortin grafting work in kalata B1 confirms the potential of using cyclotides as 
molecular scaffolds in which pharmaceutically interesting sequences can be grafted. The 
analogues were confirmed to be highly resistant to chymotrypsin digestion, highlighting the 
potential of engineered cyclotides as orally available drugs as was recently demonstrated 
[35]. Similar to the gurmarin analogues, further structure-activity work is necessary to 
improve the functionality of these analogues and especially the D-Phe/L-Phe question 
needs to be elucidated in more detail. Nonetheless, it has been demonstrated that it is 
possible to design and synthesise active melanocortin agonist analogues based on these 
highly stable disulphide frameworks. These analogues provide a novel approach for the 
development of peptide drugs targeting obesity treatment. 
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5. CONCLUSIONS AND FUTURE PERSPECTIVES 
In this PhD thesis the design, synthesis and functional characterisation of gurmarin and 
gurmarin analogues has been described. I was showed to be possible to synthesise grafted 
melanocortin analogues of gurmarin that were able to bind to the MCRs. The highest 
binding affinities were found at the MC4R which is responsible for regulation of appetite 
and energy expenditure. Consequently, these gurmarin analogues introduce a novel group 
of compounds with the possibility for treatment of obesity. Due to the stability of ICK 
peptides like gurmarin, they have been shown to have possibility for oral delivery. The 
analogues synthesised in this work need further optimisation, but the possibility for an oral 
treatment are a very promising feature of these peptides. 
 In addition, melanocortin analogues of the cyclotide kalata B1 were 
synthesised. Similarly to the gurmarin analogues, they were able to bind to the MCRs and 
one analogue bound with higher affinity to the mC4R than the endogenous agonist α-
MSH. In addition, this analogue was shown to activate the MC4R, although it was not as 
potent as α-MSH. The kalata B1 analogue was shown to be almost completely stable 
towards chymotrypsin cleavage highlighting the potential for oral bioavailability for the 
ICK peptides and cyclotides. Similarly to the melanocortin analogues of gurmarin, the 
kalata B1 analogues need further optimisation in order to achieve more MC4R potent 
peptides. 
 Besides the synthesised analogues in this work an improved redox buffer 
oxidation strategy of gurmarin was developed. This strategy produced gurmarin in high 
yields and will most likely be applicable to other ICK peptides as well. In addition, an 
orthogonal oxidation strategy was established to control the disulphide connectivity of 
gurmarin. This procedure was used to synthesise both gurmarin and a gurmarin disulphide 
isomer, and in combination with thermolysin cleavage of redox buffer oxidised gurmarin it 
was used to confirm the disulphide connectivity of this randomly oxidised gurmarin. This 
principle could also be used for the synthesis of other ICK peptides or disulphide isomers. 
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 Appendix A: Table of compounds  
I 
APPENDIX A: TABLE OF COMPOUNDS 
Peptide Structure 
  
1 *EQCVK KDELC IPYYL DCCEP LECKK VNWWD HKCIG 
2 *EQCVK KDELC IPYYL DCCEP LECKK VNWWD HKCIG 
3 *EQCVK KDELC IPYYL DCCEP LECKK VNWWD HKCIG 
4 *EQCVK KDELC IPYYL DCCEP LECKK VNWWD HKCIG 
5                                VNW 
6 *EQC             L DCCEP          WD HKC 
7 *EQC             L DCCEP          WD HKC 
8           LC IP          LECKK 
9 *EQCVK KDELC IPYYL DCCEP LECKK VNWWD HKCIG 
10 *EQCLD CCEPW DHKC 
11 *EQCLD CCEPW DHKC 
12 *EQCVK KDELA IPYYL DCCEP LEAKK VNWWD HKCIG 
13 *EQCVK KDELA IPYYL DCCEP LEAKK VNWWD HKCIG 
14 *EQCVK KDELC IPYYL DCCEP LECKK VHFRW HKCIG 
15 *EQCVK KDELC IPYYL DCCEP LECKK VHfRW HKCIG 
16 *EQCVK KDELC IPYYL DCCEP LECKK VHFRW DHKCI G 
17 *EQCVK KDELC IPYYL DCCEP LECKK VHfRW DHKCI G 
18 *EQCVK KDELC IPYYL DCCEP LECKK VNHFR WKCIG 
19 *EQCVK KDELC IPYYL DCCEP LECKK VNHfR WKCIG 
20 *EQCVK KDELC IPYYL DCCEP LECYC VNWWD HKCYC IG 
21 *EQCVK KDELC IPYYL DCCEP LECYC HfRWN AFCYC IG 
22                             YC    WD HKC 
23 *EQC             L DCCEP                YC 
24           LC IP          LEC 
25 CGETC VGGTC NTPGC TCSWP VCGHF RWGV 
*E is pyroglutamic acid. Disulphides are indicated with lines. In compound 25, the cyclic backbone is 
indicated with lines below the amino acid sequence. 
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Poster presented at the 31st European Peptide Symposium, Copenhagen, 5-9 September 
2010.  
 
 
 
 
 
  
Figure 1 The structure (PDB: 1C4E)of Gurm arin (left) and the prim ary sequence (right).  Background
 Gurm arin is a 35-residue peptide from
the plant Gym nem a sylvestre. It
functions as a sw eet taste inhibitor in
rodents(Ninom iya et al.,Am JPhysiol-
Reg I, 1995; 268(4):R1019). The
structure of Gurm arin (Figure 1) is
defined by three disulphides in a
com m on fold know n as an inhibitor
cysteine knot.
Aim s
 To do three syntheses of Gurm arin by
partial orthogonal protection group
routes differing in the position of
protection groups, and confirm the
disulphide connections of the
synthesized peptides by enzym atic
cleavage (Figure 2).
M ethods
 The peptides w ere synthesized by standard Fm oc
chem istry on a CEM Liberty peptide synthesizer.
HOBt w as added to the piperidine deprotection to
m inim ize aspartim ide form ation.
 The first disulphide w as oxidized in 0.1 M Tris-HCl
buffer(pH 7.8,0.02m M peptide),2 vol% DM SO w ith
air bubbled through until com plete oxidation w as
confirm ed byUPLC.
 The finaltw o disulphidesw ere oxidized w ith 20 eq.
iodine in 1:4 w ater:m ethanol (0.02 m M peptide)
untilcom plete oxidation w asconfirm ed byM S.
 The peptides w ere cleaved w ith 1 m ass eq.
chym otrypsin in 0.1 M TrisHCl(pH 7.8),10 m M CaCl2
24h at RT or w ith 1 m ass eq.therm olysin in 0.2 M
am m onium acetate (pH 6.5), 10 m M CaCl2 24h at
50°C.
1.R Eliasen
Novo Nordisk A/S, 
Copenhagen,
Denm ark
2. T L Andresen
Departm ent of M icro-and 
Nanotechnology, Technical 
University of Denm ark
Copenhagen, Denm ark
3. K W  Conde-Frieboes
Novo Nordisk A/S, 
Copenhagen,
Denm ark
Peptide Fragm ent Enzym e Theoretical m ass Observed m ass
Gurm arin <EQCVK KDELC IPYYL DCCEP LECKK VNW W D HKCIG
1
C3-C18 LC IP                    LECKK Therm olysin 531.78 (M +2H+) 531.79
Trityl protected <EQC L DCCEP                     W D HKC Therm olysin 861.80 (M +2H+) 861.91
<EQC LC IP     L DCCEP Therm olysin 740.28 (M +2H+) 740.29
LECKK         W D HKC Therm olysin 653.30 (M +2H+) 653.31
2
C10-C23 LC IP                    LECKK Therm olysin 531.78 (M +2H+) 531.79
Trityl protected L DCCEP Therm olysin 677.22 (M +1H+) 677.22
<EQC W D HKC Therm olysin 523.69 (M +2H+) 523.69
3
C17-C33 <EQC LC IP Therm olysin 803.34 (M +1H+) 803.35
Trityl protected L DCCEP LECKK         W D HKCIG Therm olysin 982.40 (M +2H+) 982.42
<EQCVK KDELC IPY Chym otrypsin 774.36 (M +2H+) 774.37
L DCCEP LECKK VNW W D HKCIG Chym otrypsin 1339.58 (M +2H+) 1339.60
Results
 The synthesisofthe peptide w ith trityl
protected cys-3 and cys-18 produced a
m ixture oftw o products.One ofthese
w asidentified asthe native peptide by
the fragm ent in figure 3 and another
fragm ent containing tw o native
disulphides(second fragm ent,table 1).
In this fragm ent one disulphide w as
oxidized selectively in the airoxidation
of the trityl protected cysteines and
consequently all three disulphides in
thispeptide are native.
 In all three peptides non-natural
disulphides w ere produced in the
iodine oxidation as the m ain product.
Disulphide form ation betw een
cysteines that are close in the prim ary
sequence seem sto be favoured.
20 eq. I2
1:4 H2O :CH3O H
0.02 m M  peptide
Trt                 Acm     Trt     Acm
Acm                        Acm
1. TFA/Tips/EDT/H2O
2. 0.1 M  Tris-HCl (pH 7.8), 
2 vol%  DM SO
Acm                                 Acm
Acm                       Acm
Chym otrypsin/therm olysin
1:1 (w :w )
Table 1 Fragm ents obtained from cleavage w ith therm olysin or chym otrypsin of the three differently
synthesized peptides.Native disulphidesare indicated w ith lightblue lines,non-native disulphidesare red.
Conclusions
 The position ofthe protection groups
are critical for the outcom e of the
disulphide oxidation.
 The synthesis of native Gurm arin is
possible w ith thissynthesisroute.
Figure 2 The synthesis route and cleavage of the
peptide w ith tritylprotected cys-3 and cys-18.
Figure 3.Sequence and m assspectrum ofa native
disulphide fragm ent obtained by cleavage w ith
therm olysin.
The three peptides are identified by the trityl protected cysteines in the first colum n. <E is pyroglutam ate.
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APPENDIX C: PROCEEDINGS PAPER 
Proceedings paper from the 31st European Peptide Symposium, Copenhagen, 5-9 
September 2010.  
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Copenhagen, 5-9 September 2010. Ed. M. Lebl, M. Meldal, K. J. Jensen and T. Høeg-Jensen. European 
Peptide Society, 2010. 144-5. Print. 
Proceedings of the 31st European Peptide Symposium 
Michal Lebl, Morten Meldal, Knud J. Jensen, Thomas Hoeg-Jensen (Editors) 
European Peptide Society, 2010 

Fig. 1. Sequence and mass spectrum of a 
native disulphide fragment obtained by 
cleavage with thermolysin. 
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 Fig. 2. The structure (PDB: 1C4E) of Gurmarin (left) and the primary sequence (right). 
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Handling a tricycle: orthogonal versus random oxidation of the tricyclic inhibitor cystine 
knotted peptide gurmarin 
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Abstract 
Gurmarin is a 35 amino acid peptide with three disulfide bridges in an inhibitor cystine 
knot. It is found in the plant Gymnema sylvestre, and has been identified as a sweet taste 
inhibitor in rodents. In this article we provide an efficient route for the synthesis of 
gurmarin by a controlled random oxidation strategy. We compared two oxidation 
procedures to form the three disulfide bridges. In the first, based on random oxidation, 
reduced gurmarin was synthesized using trityl for cysteine protection, and oxidized for 48 
hours in a Tris-HCl buffer containing cystamine and reduced glutathione to facilitate 
disulfide scrambling. The second was based on step-wise deprotection followed by 
oxidation in which the cysteine pairs are orthogonally protected with tert-Butylthio, trityl 
and acetamidomethyl. To verify that the native gurmarin oxidation product was obtained, 
thermolysin cleavage was used. Cleavage of random oxidized gurmarin showed two 
possible disulfide combinations; the native and a non-native gurmarin disulfide isomer. The 
non-native isomer was therefore synthesized using the orthogonal deprotection-oxidation 
strategy and the native and the non-native gurmarin isomers were analyzed using UPLC. It 
was found that the random oxidation procedure leads to native gurmarin in high yield. 
Thus, the synthetic route was simple and significantly more efficient than previously 
 Appendix D: Accepted manuscript  
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reported syntheses of gurmarin and other cysteine rich peptides. Importantly, native 
gurmarin was obtained by random oxidation, which was confirmed by a synthetic approach 
for the first time. 
 
Highlights 
The inhibitor cystine knotted peptide gurmarin is synthesized using a random oxidation 
strategy and an orthogonal oxidation strategy. 
A thermolysin cleavage of random oxidized gurmarin shows two possible disulfide 
combinations. 
The non-native gurmarin disulfide isomer is synthesized using the orthogonal strategy and 
compared with random oxidized gurmarin using UPLC. 
A synthetic approach is used for the first time to confirm the structure of a random 
oxidized inhibitor cystine knotted peptide. 
 
Keywords 
Gurmarin 
Peptide synthesis 
Inhibitor cystine knot 
Disulfide formation 
Orthogonal oxidation 
 
Abbreviations 
4-PDS, 4,4-dithiodipyridine; Acm, acetamidomethyl; DIPEA, diisopropylethylamine; 
DMSO, dimethylsulfoxide; EDT, ethanedithiol; ICK, inhibitor cystine knot; NMP, N-
methylpyrrolidone; Pyr, pyroglutamic acid; StBu, tert-Butylthio; TFA, trifluoroacetic acid; 
TIPS, triisopropylsilane; Trt, trityl; UPLC, Ultra Performance Liquid Chromatography. 
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1 Introduction 
Gurmarin is a 35 amino acid peptide isolated from leaves of the plant Gymnema sylvestre [10]. 
The tertiary structure of gurmarin is determined by three disulfides in an inhibitor cystine 
knot (ICK) (figure 1) [7,8]. Gurmarin was identified as a sweet taste suppressor in rodents 
[10,16,17] and in Ayurvedic system of medicine the leaves and root of Gymnema sylvestre has 
been used for treating diabetes and obesity [14]. This effect is believed to be caused by 
gymnemic acids, a mixture of at least 17 saponins, but gurmarin is also expected to be part 
of the effect [10,14]. Cystine knotted peptides have been suggested as scaffolds for drug 
development, due to their increased stability induced by the disulfide knot and their 
potential oral bioavailability [6,23]. 
The folding of cystine knotted peptides can essentially be done in two 
different ways. Using a redox buffer in which the disulfides scramble until they reach the 
thermodynamically most favorable conformation [4,17] or by using orthogonal cysteine 
side chain protection groups during solid phase peptide synthesis. The latter allow for 
selective formation of one disulfide at a time [3,12,19]. When using a redox buffer to 
oxidize a cystine knotted peptide, the peptide is dissolved in a slightly basic buffer 
containing a mixture of low molecular weight disulfides and sulfides, which facilitate 
scrambling of non-native disulfides combinations into the thermodynamically most 
favorable conformation [1,2,18]. The selective disulfide formation requires three pairs of 
orthogonal side chain protection groups. Cysteine protection groups can be labile to acid, 
base, metal ions or reducing agents [2,11]. The most commonly used cysteine protection 
group in Fmoc-SPPS is trityl [11], which can be removed with 95% TFA in the presence of 
scavengers [24]. Another common protection group is acetamidomethyl (Acm) [11], which 
is stable towards TFA. When treated with iodine, the Acm-protected cysteine is activated 
and forms a disulfide concurrently [20]. The two mentioned protection groups are stable 
towards reducing agents, and consequently tert-Butylthio (StBu) can be used in combination 
with these, since it can be removed with thiols or phosphines [11,22]. The free thiols can 
be oxidized using a variety of methods, both in solution and on-resin. It is important to 
maintain acidic pH during the oxidations to minimize disulfide scrambling. DMSO or 4,4-
dithiodipyridine (4-PDS) can be used to oxidize thiols at acidic pH via activated disulfide 
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intermediates [5,21]. By using 4-PDS it is possible to oxidize cysteines directly in the acidic 
acetonitrile/water solvent typically used in preparative HPLC purification. 
The selective disulfide formation method ensures that the right disulfide 
combination is obtained. However, the procedure is often laborious and side reactions can 
occur during the continuous deprotections and oxidations [15]. The random oxidation 
method has the disadvantage that multiple disulfide combinations can be obtained. 
Nonetheless, it is expected that the native product will be formed in a random redox buffer 
oxidation, since the native product most likely has the highest thermodynamic stability [15]. 
However, this is not always the case [12]. Consequently, structure confirmation is essential 
when random oxidation is used. Because of the neighboring cysteines in ICK peptides, the 
structure confirmation cannot be done by an enzymatic fragmentation alone, since no 
cysteine specific proteases exist.  
 
 
Figure 1. The structures of and numbering of gurmarin, iso-gurmarin (1) and peptide fragments obtained in a 
thermolysin cleavage of random oxidized gurmarin.   
 
 In this work gurmarin was synthesized both by random oxidation and by 
selective formation of the three disulfides using orthogonal cysteine side chain protection 
groups. The two different oxidation routes are illustrated in figure 2. To confirm the 
combination of the disulfides, the random oxidized gurmarin was cleaved with thermolysin 
to obtain one fragment (4) containing one disulfide from Cys10 to Cys23 and one fragment 
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(3) containing two disulfides from Cys3 to Cys18 and Cys17 to Cys33. To ensure that 
fragment 3 in fact has the native conformation and not the non-native Cys3-Cys17 and 
Cys18-Cys33 conformation (5), a non-native gurmarin disulfide isomer (1) with this 
disulfide combination was synthesized using the orthogonal oxidation strategy. Finally, the 
two orthogonal oxidized peptides were compared with the random oxidized gurmarin by 
co-injection of the peptides on UPLC. Consequently, the disulfide pattern was confirmed 
by a synthetic approach. 
 
Figure 2. Illustration of the two oxidation strategies. From the top is the orthogonal oxidation and from the 
bottom is the random oxidation. Gurmarin is highlighted by the dashed box. The numbers to the left are 
used to refer to synthesis intermediates. 
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2 Materials and methods 
2.1 Materials 
Resin and amino acids were purchased at Novabiochem, Germany. Thermolysin, 
glutathione, cystamine and 4-PDS were purchased at Sigma Aldrich, Germany. 
 
2.2 General Solid Phase Peptide Synthesis 
The peptides were synthesized using Fmoc-chemistry using a preloaded Fmoc-Gly-Wang 
polystyrene LL resin in 0.1 mmol scale on a CEM Liberty microwave peptide synthesizer 
(CEM Corporation, NC) using standard protocols. Oxyma Pure, diisopropylcarbodiimide 
and amino acids were used for coupling in 5-10 fold excess over theoretical loading, and 
5% piperidine in NMP with 0.05 M HOBt was used for Fmoc-deprotection. HOBt was 
added to reduce aspartimide formation of Asp16 [13]. Glu2 was coupled twice. Cys-
residues and His31 were coupled twice at 50 °C. 
 
2.3 Redox buffer oxidation 
The peptide was synthesized as described in section 2.2. Cysteines were protected with 
trityl. The peptide was cleaved with 92:4:2:2 TFA:ethanedithiol:water:triisopropylsilane, 
precipitated in diethyl ether (crude purity 54%) and purified on a Waters Delta Prep 4000 
using a Waters XBridge Prep C18 OBD column (Waters Corporation, MA), 5 µm, 30x150 
mm. Mobile phases were 0.1% TFA in water and 0.1% TFA in acetonitrile. Peptide 
concentration was determined by Chemiluminescent Nitrogen Detection using an Antek 
8060 CLND HPLC detector (PAC, TX) [9]. Reduced gurmarin (10) was dissolved at 0.02 
mM in a 0.1 M Tris-HCl (pH 7.8), 1 mM reduced glutathione, 1 mM cystamine redox 
buffer and stirred for 48 hours. Gurmarin was purified as described above and fractions 
were analyzed on Waters Acquity UPLC using a BEH, 1.7 μm, 2.1 x 150 mm column and a 
gradient of 5-95 % of acetonitrile containing 0.05 % TFA against 0.05 % TFA in water 
over 16 min, flow: 0.4 ml/min. Peptide MW was confirmed using Agilent 6230 TOF 
LC/MS (Agilent Technologies, CA). Peptide purity: 97.3 %, retention time 5.8 min. 
Observed MW 1052.5 (M+4H+)/4 (expected 1052.5).  
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2.4 Orthogonal oxidation 
The peptide was synthesized as described in section 2.2. Cys3 and Cys18 were Acm-
protected, Cys10 and Cys23 were StBu-protected, while Cys17 and Cys33 were trityl-
protected. StBu was removed (7) using 2-4 x 24 h 80:20:1 
NMP:mercaptoethanol:diisopropylethylamine. The first disulfide was formed using 4:1 
NMP:DMSO for 2 x 4 h. Peptide 7 was cleaved from the resin using the same conditions 
as described in section 2.3, which also removed the trityl-protection groups. Peptide 8 was 
purified after cleavage from the resin. The second disulfide was formed using 10 eq. of 4-
PDS for 2 h and a peptide concentration of 0.05 mM directly in pooled fractions from the 
preparative HPLC diluted with water. After purification, the final disulfide was formed 
using 100 eq. of I2 in 4:1 acetic acid:water  for 2 h and a peptide concentration of 0.05 mM 
(small amounts of acetonitrile and TFA from the preparative HPLC are included in the 
water part for simplicity. Exact amounts were not determined). The oxidation was stopped 
by adding ascorbic acid, the reaction mixture was diluted to 20% acetic acid and purified 
using a ODDMS 120A, 5 μm, YMC 4x125 mm column (FeF Chemicals, Denmark). All 
reactions were done at room temperature. The peptides were analyzed as described above. 
Synthesis of gurmarin. Purity: 76.6 %, retention time 5.7 min. Observed MW 1052.5 
(M+4H+)/4 (expected 1052.5). Synthesis of iso-gurmarin (1). Purity: 83.7 %, retention time 
5.3 min. Observed MW 1052.6 (M+4H+)/4 (expected 1052.5). 
 
2.5 Thermolysin cleavage 
A thermolysin cleavage was done with 0.1 mg of random oxidized gurmarin and 0.1 mg 
thermolysin in 0.6 ml 0.2 M ammonium acetate (pH 6.5), 10 mM calcium chloride at 50 
degrees centigrade for 4 h. The fragments obtained from the cleavage were analyzed by 
LC/MS.  
 
3. Results 
3.1 Redox buffer oxidation of gurmarin  
Peptide 10 was synthesized using trityl as protection group for all cysteines. Peptide 10 was 
oxidized for 48 h in a redox buffer until the major peak observed on UPLC did not 
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increase as depicted in figure 3, which shows the progress of the oxidation. The yields and 
MW of peptide 10 and gurmarin are summarized in table 1. When peptide 10 was oxidized 
without prior purification very little oxidized peptide was isolated (data not shown). 
  
 
Figure 3. UPLC chromatograms showing the progress of the random oxidation. The gradient is 5-60 % of 
acetonitrile containing 0.05 % TFA against 0.05 % TFA in water for 3.5 min. A Waters BEH column, 1.7 μm, 
2.1 x 50 mm was used. 
 
3.2 Orthogonal oxidation of gurmarin  
Peptide 6 was synthesized with orthogonal cysteine side chain protection groups as 
illustrated in figure 2. Cys10 and Cys23 was StBu deprotected on resin 2-4 x 24 h until full 
deprotection was determined by LC/MS in a test cleavage. The amount of time required 
for the deprotection changed with different batches of the same resin. In some batches it 
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was possible to deprotect StBu in 5x60 min at 60 °C using a microwave oven. Following 
the deprotection, the cysteines were oxidized with DMSO, and peptide 8 was cleaved from 
the resin and purified. When 4-PDS was used instead of DMSO in the first oxidation, it 
was observed that both cysteines reacted with 4-PDS instead of being oxidized even 
though sub-stoichiometric amounts of 4-PDS were used. Peptide 9 was formed using 4-
PDS in pooled preparative HPLC fractions containing peptide 8. The Acm-protected 
cysteines were oxidized with iodine and finally gurmarin was purified. The yield and MW of 
the intermediates and gurmarin are summarized in table 1 and depicted in figure 4. 
 
Table 1. MW and yields of the intermediates and final products in the two oxidation strategies. 
Oxidation Product  Expected MWa Observed MWa  Yield (%) 
   (M+4H+)/4 (M+4H+)/4 step  overall 
Redox buffer Reduced gurmarin 10 1054.0 1054.0    24.7 
 Oxidized gurmarin  1052.5 1052.5 57.1   14.1 
Orthogonal StBu deprotectedb 7 1089.5 1089.7c    
 Mono-disulfide 8 1089.0 1089.2c    7.0 
 Bis-disulfide 9 1088.5 1088.7c 69.2   4.8 
 Tris-disulfide  1052.5 1052.5 11.4   0.55 
a monoisotopic mass. b the mass was found in a TFA test cleavage and consequently only Acm protection 
groups were not removed c the error in the observed MW was caused by an inaccuracy in the instrument 
calibration. 
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Figure 4. LC-MS analysis of the intermediates and final product of the orthogonal synthesis. The 
intermediates are indicated with numbers, expected MW (M+4H+)/4 and observed retention time from the 
LC-MS. The mass spectrum and chromatogram for each peptide is shown below. The MW observed for 6 
and 7 corresponds to the Trt deprotected products from a TFA test cleavage. 
 
Three orthogonal on-resin deprotections and disulfide formations were attempted using 
monomethoxytrityl as protection group instead of trityl. This protection group was 
deprotected using 1% TFA for 10 x 2 min. Unfortunately, it was not possible to form the 
second disulfide on resin using DMSO. When 4-PDS was used, both cysteines reacted with 
4-PDS instead of forming the disulfide as observed in the first disulfide formation. Only 
when using less than 0.1 eq. of 4-PDS, a small amount of the second disulfide was 
observed. 
 
3.3 Thermolysin cleavage of gurmarin  
The random oxidized gurmarin was cleaved with thermolysin, which cleaves the N-
terminal peptide bond of hydrophobic amino acids. When the cleaved peptide was 
evaluated on LC-MS, four major peaks appeared (figure 5). Peak 1 contained fragment 2 
(exp. MW 418.20 (M+1H+)), peak 2 the bis-disulfide fragment 3 or 5 (exp. MW 574.86 
(M+3H+)/3), peak 3 the mono-disulfide fragment 4 (exp. MW 531.78 (M+2H+)/2), while 
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peak 4 contained non-cleaved gurmarin (exp. MW 1052.47 (M+4H+)/4). All MW are 
monoisotopic masses. 
 
 
Figure 5. LC-MS analysis of thermolysin cleaved gurmarin. On top is the chromatogram and below are mass 
spectra of the major m/z peaks observed in the four highlighted peaks on the chromatogram. 
 
3.4 Orthogonal oxidation of non-native iso-gurmarin (1) 
The thermolysin cleavage of the random oxidized gurmarin indicated that two disulfide 
combinations were possible. The bis-disulfide peptide fragment observed in peak 3 in 
figure 5 can be the native fragment 3 or the non-native fragment 5. To investigate which of 
the two combinations that were produced in the random oxidation, the orthogonal 
oxidation strategy was used to synthesize the non-native iso-gurmarin (1). In general, the 
yields of the synthesis steps were comparable to the synthesis of gurmarin, and the overall 
yield was 0.34 %. However, an inseparable by-product from the iodine oxidation with an 
additional MW of 109 Da was present in the finished product, which broadened the peak 
observed on UPLC. 
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3.5 Comparison of orthogonal oxidized and random oxidized gurmarin 
Random oxidized gurmarin was co-injected with both orthogonal oxidized gurmarin and 
peptide 1 on UPLC, to investigate whether the products were separable. One sharp peak 
was observed when gurmarin was co-injected (figure 6a), while two clearly separable peaks 
appeared when the peptide 1 was co-injected (figure 6b). 
 
 
Figure 6. UPLC chromatograms of the two co-injection runs. The gradient is 5-95 % of acetonitrile 
containing 0.05 % TFA against 0.05 % TFA in water for 16 min. A Waters BEH column, 1.7 μm, 2.1 x 150 
mm was used. Retention times are indicated next to the peaks. a) Co-injection of random oxidized gurmarin 
and orthogonal oxidized gurmarin. b) Co-injection of random oxidized gurmarin and orthogonal oxidized 
peptide 1. 
 
4 Discussion 
In this work, the ICK gurmarin was synthesized using two different oxidation strategies. 
One in which the peptide was oxidized randomly in a redox buffer and one using three 
orthogonal cysteine side chain protection groups that allowed the selective formation of 
one disulfide at a time. The orthogonal oxidation route was also used to synthesize a non-
native disulfide isomer 2 that was separable by analytical UPLC. 
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 The yield in the random oxidation strategy was 14.1 %. In previous reported 
random oxidations of gurmarin the yields were 0.7 % and 2.4 % [8,17]. Thus, the yield in 
this synthesis is significantly increased. This is mainly due to an increase in the yield of 
reduced gurmarin (10), which could be a consequence of reduction of aspartimide 
formation of Asp16 by adding HOBt to the piperidine deprotection. In previously reported 
orthogonal oxidations of peptides with three disulfides, overall yields were not reported 
[3,12]. However, compared to these examples the orthogonal oxidation method in this 
work is less laborious and time consuming. The reason why deficit 4-PDS was able to react 
with both cysteines in the first disulfide formation is considered to be due to the resin 
loading being lower than stated on the product. 
 When three disulfides are formed by six cysteine residues, 15 possible 
disulfide combinations can be obtained. A thermolysin cleavage of the random oxidized 
gurmarin showed that only one of two combinations, the native and a non-native, was 
possible. These two disulfide isomers of gurmarin were synthesized using the orthogonal 
oxidation route. When orthogonal oxidized gurmarin was co-injected with the redox buffer 
oxidized gurmarin on analytical UPLC only one peak appeared. This confirms the native 
disulfide combination of the random oxidized gurmarin. To our knowledge, this is the first 
fully orthogonal synthetic approach to confirm the structure of an ICK peptide. 
 A previous attempt to synthesize an ICK peptide by both random and 
orthogonal oxidation was unsuccessful [12]. In this example the native conformation was 
only obtained using the orthogonal strategy. In the random oxidation one equivalent of 2-
PDS was used, compared to 16.7 equivalents of the glutathione/cystamine redox pair in 
this work. It is likely that excess of a redox pair is necessary to allow the peptide to 
scramble until the most thermodynamically favorable conformation is obtained. 
 In the orthogonal strategy, three on-resin disulfide formations were 
attempted without success. If the protection groups had been placed at different cysteine 
pairs, thereby changing the order in which the disulfides were formed, it is possible that 
three on-resin disulfide formations could have succeeded. However, it is also possible that 
the peptide is not able to fold into the disulfide knot while attached to the resin due to 
steric hindrance by the resin polymer and side chain protection groups.  
 Appendix D: Accepted manuscript  
XXI 
4.1 Conclusion 
In the synthesis of gurmarin using the two oxidation strategies described herein, the 
random oxidation is superior to the orthogonal oxidation regarding yield, time and 
simplicity. However, it is difficult to determine the disulfide combination when oxidizing 
ICK peptides randomly in a redox buffer. In this work the combination was determined by 
a synthetic approach, which proved that the same product was obtained in both strategies. 
This has been reported not always to be the case when synthesizing ICK peptides. The 
orthogonal oxidation strategy is more laborious, but it removes the uncertainty regarding 
the disulfide combination. The on-resin oxidation of the first disulfide reduces the number 
of purifications, and consequently increases the overall yield. The final two oxidations are 
simple and could be made directly in diluted HPLC fractions, thereby reducing the overall 
synthesis time. 
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Capsule 
Background: Cyclotides are useful scaffolds to 
stabilize bioactive peptides. 
Results: Four melanocortin analogues of kalata 
B1 were synthesized. One is a selective MC4R 
agonist. 
Conclusion: The analogues retain the native 
kalata B1 scaffold and introduce a designed 
pharmacological activity, validating cyclotides 
as protein engineering scaffolds. 
Significance: A novel type of melanocortin 
agonist has been developed, with potential as a 
drug lead for treating obesity. 
 
Abstract 
Obesity is an increasingly important global 
health problem that lacks current treatment 
options. The melanocortin receptor 4 (MC4R) 
is a target for obesity therapies since its 
activation triggers appetite suppression and 
increases energy expenditure. Cyclotides have 
been suggested as scaffolds for the insertion 
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and stabilization of pharmaceutically active 
peptides. In this study we explored the 
development of appetite reducing peptides by 
synthesizing MC4R agonists based on the 
insertion of the His-Phe-Arg-Trp sequence 
into the cyclotide kalata B1. The ability of the 
analogs to fold similarly to kalata B1 but 
display MC4R activity was investigated. Four 
peptides were synthesized using Boc peptide 
chemistry with a C-terminal thioester to 
facilitate backbone cyclization. The structures 
of the peptides were found to be similar to 
kalata B1, evaluated by Hα NMR chemical 
shifts. KB1[GHFRWG;23-28] had a Ki of 29 
nM at the MC4R and was 107 or 314 times 
more selective over this receptor than MC1R 
or MC5R respectively, and had no detectable 
binding to MC3R. The peptide had higher 
affinity for the MC4R than the endogenous 
agonist, α-melanocyte stimulation hormone 
(MSH), but was less potent at the MC4R, with 
an EC50 of 580 nM for activation of the 
MC4R. In conclusion, we synthesized 
melanocortin analogs of kalata B1 that 
preserve the structural scaffold and display 
receptor binding and functional activity. 
KB1[GHFRWG;23-28] is potent and selective 
for the MC4R. This compound validates the 
use of cyclotides as scaffolds, and has the 
potential to be a new lead for the treatment of 
obesity. 
 
Introduction 
Obesity is an increasing problem world-wide 
with 1.5 billion adults estimated to be 
overweight (BMI above 25 kg/m2) and 500 
million obese (BMI above 30 kg/m2) in 2008 [1]. 
These statistics are alarming given that obesity is 
associated with a risk of developing a variety of 
debilitating diseases, including type 2 diabetes, 
cardiovascular disease and hypertension [2-4]. 
To prevent or reduce obesity and the risk of 
related diseases, regular exercise and a healthy 
diet are very effective [5], but in high risk 
patients drug treatment is also necessary [6]. 
Currently only two drugs are approved for the 
treatment of obesity, i.e., orlistat and 
phentermine. The FDA withdrew sibutramine in 
2010 because of increased risk of cardiovascular 
events [7]. Although drugs currently on the 
market for other indications are undergoing 
clinical trials for their potential to treat obesity, 
there is still an urgent need for new drugs 
targeting the world-wide obesity problem. 
One approach to the development of 
drugs for the treatment of obesity is to target the 
melanocortin system, which comprises a family 
of five G-protein coupled receptors, the 
melanocortin receptors (MCR), named MCR1-5 
in the order of their discovery [8-12]. The 
endogenous peptide agonists, 
adrenocorticotropic hormone (ACTH) and α-, β- 
and γ- melanocyte stimulating hormone (MSH), 
all derived from the precursor protein pro-
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opiomelanocortin, form part of the system, in 
addition to the inverse agonists agouti protein 
and agouti-related protein (AGRP).  
The five MCR receptors are distributed 
throughout the body and are associated with a 
variety of physiological effects. MC1R is mainly 
present in melanocytes and melanoma cells 
[8,9]. MC2R is present in the adrenal cortex, 
where it regulates steroidogenesis, and is only 
activated by ACTH, in contrast to the other 
MCRs [8]. MC3R is mainly expressed in the 
arcuate nucleus [13], but is also present in the 
gut [10]. MC4R is found throughout the brain 
[14] and in the spinal cord and dorsal root 
ganglions [15]. Stimulation of MC4R reduces 
food intake and increases the metabolic rate in 
mice [16], which makes it an interesting target 
for the treatment of obesity. MC5R is distributed 
throughout the body with high levels found in 
skeletal muscle, brain and exocrine glands, and 
has a variety of functions [12,17,18].  
The MSH peptides and ACTH share the 
tetrapeptide His-Phe-Arg-Trp pharmacophore, 
which is the shortest peptide active on the MCRs 
[19]. Various modifications to this tetrapeptide 
have been made to explore the role of individual 
amino acids. Substitution of Met4 with 
norleucine (Nle) and modifying the 
conformation of Phe7 to D-Phe in α-MSH (see 
Table 1), yielded a stable subnanomolar agonist 
named NDP-α-MSH [20]. Additionally it has 
been shown that the His-D-Phe-Arg-Trp 
tetrapeptide alone has nanomolar activity on the 
MC4R [21]. In another study a truncated 
analogue of the inverse agonist AGRP was 
turned into a full agonist by exchanging the 
binding sequence with His-D-Phe-Arg-Trp [22]. 
These findings suggest that it might be possible 
to graft the His-Phe-Arg-Trp sequence and 
related modified sequences into stable peptide 
frameworks to develop novel MCR agonists. 
The motivation for the grafting is to place the 
bioactive tetrapeptide in a molecular context 
where is will be less susceptible to proteolysis 
and will have more favorable biopharmaceutical 
properties than the isolated peptide sequence. 
The concept of developing MC4R 
agonists for the treatment of obesity has been 
around for more than a decade, as reviewed by 
Emmerson et al. [23] and Wikberg and Mutulis 
[24]. Despite strenuous efforts, no compounds 
have reached clinical trials for the treatment of 
obesity. The similarity between the various 
MCR receptors, which makes it challenging to 
make selective agonists, and the generally low 
half-lives of peptides in vivo [23] have probably 
contributed to this lack of success.  
Recent discoveries of naturally 
occurring stable peptides offer the potential to 
overcome some of the limitations of peptides as 
drug leads. In the mid 1990’s several ultra-stable 
peptides that had both a cyclic backbone and 
three disulfide bonds forming a cystine knot 
were discovered [25-28]. The most extensively 
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studied of these is the 29 residue peptide kalata 
B1 found in the African plant Oldenlandia 
affinis [26], which  originally attracted attention 
because of its reported uterotonic activity [29]. 
More recently it has been reported to have 
antimicrobial and cancer cell cytotoxic activity 
[30] as well as a range of other activities. Its 
biological function in the plant is thought to be 
as a host defense pesticidal agent, since it 
reduces the growth of the larvae of the crop pest 
Helicoverpa punctigera [31]. Following 
additional discovery efforts [32-36] since these 
early studies, the group of cyclic cystine knotted 
(CCK) peptides now comprises several hundred 
sequences and been given the name cyclotides 
[33,37]. They are exceptionally stable towards 
enzymatic or thermal degradation because of 
their cyclic backbone and cystine knot 
[26,28,38]. Due to their stability and large 
sequence variation in nature, cyclotides have 
been suggested as promising scaffolds for the 
grafting of pharmaceutically interesting peptides 
to stabilize them [33,39]. There are six backbone 
loops decorating the cystine knot core, and these 
offer opportunities for conformational control of 
a variety of peptide epitopes. In addition to being 
amenable to solid phase peptide synthesis 
[30,40], cyclotide libraries have recently been 
expressed in bacterial cells [41] thus providing 
alternative routes to their manufacture. 
There are currently only a few 
examples demonstrating the grafting of 
biologically active sequences into cyclotides or 
related acyclic cystine knot scaffolds. For 
example, Clark et al. demonstrated that it was 
possible to substitute selected amino acids in 
loop 5 of kalata B1 to remove intrinsic 
hemolytic activity but retain the native fold [42] 
and later studies on this framework 
demonstrated efficacy for grafted antiangiogenic 
sequences [43] and bradykinin antagonists [44]. 
Thongyoo et al. changed the specificity of the 
trypsin inhibitor cyclotide, MCoTI-II, towards 
other proteases with one to three amino acid 
substitutions [45] and Chan et al. reported a 
novel angiogenic agent based on this framework 
[46]. In acyclic cystine knotted peptides, Reiss et 
al. successfully grafted platelet aggregation 
inhibiting sequences [47], and as mentioned 
above, AGRP was turned into a full agonist on 
the melanocortin receptors [22]. 
In the current study, kalata B1 was used as 
a scaffold for the insertion (grafting) of 
melanocortin receptor activating sequences. The 
grafted sequences are shown in Figure 1 along 
with the NMR-derived structure of kalata B1. 
These analogues have the potential to become 
leads for a new class of melanocortin receptor 
agonists for the treatment of obesity. More 
broadly, they will expand knowledge on the 
applicability of cyclotides as scaffolds. 
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Experimental procedures 
Peptide synthesis 
Peptides were synthesized manually by Boc 
solid phase peptide synthesis on a Boc-Gly-
PAM resin using 2-(1-H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate 
(HBTU) or 2-(6-chloro-1-H-benzotriazol-1-yl)-
1,1,3,3-tetramethylaminium 
hexafluorophosphate (HCTU) as coupling 
reagents, as described previously [42]. 
Mercaptopropionic acid was used as a linker to 
facilitate backbone cyclization by native 
chemical ligation. Peptides were cleaved from 
the resin using hydrogen 
fluoride/cresol/thiocresol (50:4:1 v/v/v), 
precipitated in diethylether and lyophilized. The 
crude peptides were purified using HPLC with a 
gradient of 25-45% solvent B (90% acetonitrile, 
0.1% TFA in water) against solvent A (0.1% 
TFA in water) over 40 minutes. A Phenomenex 
C18 column was used and absorbance measured 
at 280 nm. Backbone cyclization and disulfide 
bonds were formed using 0.1 M ammonium 
bicarbonate (pH 8.2), isopropanol (50:50, v/v) 
buffer for 48 hours, at a peptide concentration of 
0.2 mg/ml. At 0 h and 24 h, 1 mM reduced 
glutathione was added. The oxidized peptides 
were purified on HPLC with 30-50% solvent B 
over 60 minutes. The peptides were 
characterized using electrospray ionization mass 
spectrometry; the purity was determined by RP-
UPLC and the peptides were quantified using a 
chemiluminescent nitrogen detector [48].  
 
NMR 
Peptides were dissolved at a concentration of 
approximately 1 mM in 10% D2O and 90% H2O. 
Spectra were recorded at 298 K on a Bruker 
AVANCE 600 MHz NMR spectrometer. Two-
dimensional spectra recorded included TOCSY, 
NOESY and DQF-COSY. The mixing times for 
the TOCSY and NOESY spectra were 80 ms and 
200 ms respectively. The processed spectra were 
analyzed using the program CcpNMR Analysis, 
University of Cambridge, UK. Three-
dimensional structures were calculated from the 
recorded two-dimensional spectra using 
CYANA as described previously [49]. Structures 
were analyzed using Molprobity and 
PROMOTIF [50] and displayed using MolMol 
[51] and PyMol [52]. Structures and chemical 
shifts have been deposited in the protein data 
bank (PDB ID 2lur) and Biomagnetic Resonance 
Bank (BMRB ID 18536) respectively. 
 
Melanocortin assays 
Melanocortin receptor binding assays were 
conducted as previously described [53]. Each 
assay was performed in duplicate and three 
assays were done on each receptor. Peptides 
(3pM to 3µM) were incubated with 
homogenized membranes from baby hamster 
kidney cells expressing the various MCRs and 
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125I-NDP-α-MSH (around 60,000 counts/min). 
The incubation was stopped after 1 hour by 
filtration through polyethylenimine treated filter 
plates. Scintillation liquid was added to the 
plates and the radioactivity was counted. 
The cAMP activity assays were 
conducted on baby hamster kidney cells 
expressing the MC4R, using the FlashPlateTM 
assay as previously described [53]. Cells and 
peptide (100 fM to 10 µM to) were incubated 
and shaken for 30 min at room temperature. 
Detection mix was added according to 
FlashPlate protocol, shaken for 30 min and 
incubated overnight. The amount of cAMP 
produced was measured by displacement of 
radiolabeled cAMP bound to anti-cAMP 
antibodies in accordance with the FlashPlate 
protocol. 
The data analyses from the receptor assays 
were performed as described previously [53], 
using the program GraphPad Prism, GraphPad 
Software, USA. IC50 values were calculated 
using a nonlinear regression model and Ki values 
were calculated from the IC50 values. The 
potency at the MC4R was determined as EC50 
values, calculated by nonlinear regression of the 
activity assay data. 
 
Enzymatic cleavage assays 
Peptides were incubated with chymotrypsin (1:5 
w/w enzyme/peptide ratio) at 37°C. For α-MSH 
the ratio was 1:10 w/w enzyme/peptide in order 
to have close to equal molar ratios for all 
peptides. Samples were aliquoted out and 
quenched with TFA before analysis on UPLC. 
Peak heights were used to calculate the amount 
of intact peptide.    
 
Results 
Design, synthesis and characterization of the 
grafted peptides 
Four melanocortin analogues of kalata B1 were 
synthesized using solid phase Boc-chemistry. 
The sequences of the peptides are shown in 
Table 1. They are named to reflect the grafted 
epitopes incorporated into the kalata B1 (kB1) 
sequence. For example, kB1[HFRW;24-27] 
indicates replacement of residues 24-27 in loop 6 
of kalata B1 (kB1) with the -HFRW (His-Phe-
Arg-Trp) tetrapeptide sequence. In this case the 
tetrapeptide is flanked by the remaining native 
amino acids in loop 6, i.e., T at the N-terminal 
side and PV at the C-terminal side, making the 
total composition of loop 6 THFRWPV in place 
of the native TRNGLPV. To account for the 
possibility that direct replacements might 
constrain the bioactive tetrapeptide in a non-
active conformation other grafts were made 
where flanking glycine residues were used in 
place of the native kalata B1 residues. 
The peptides were assembled attached 
to a C-terminal mercaptopropionic acid linker to 
facilitate subsequent cyclization of the termini. 
The linear precursor peptides were synthesized 
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with V21 as the C-terminus, since this allowed 
the synthesis of one batch of resin to which was 
coupled the first 22 identical amino acids. This 
batch was subsequently split to synthesize the 
four analogues. Loop 6 was chosen as the site 
for grafting the melanocortin sequence, since it 
is the largest of the inter-cysteine loops in kalata 
B1. In addition, the structure of kalata B1 shown 
in Figure 1 indicates that the other loops are not 
in close proximity with loop 6 and therefore are 
not likely to interfere with the presentation of the 
grafted melanocortin sequence to the MCRs.  
The peptides were oxidized and 
cyclized in a single step at 0.2 mg/ml 
concentration in a 0.1 M ammonium bicarbonate 
(pH 8.2), isopropanol (50:50, v/v) buffer for 48 
hours with 1 mM reduced glutathione added at 0 
and 24 hours. The chromatograms from the 
purification of the folded peptides are shown in 
Figure 2.  
The late eluting peaks were purified 
and analyzed by NMR spectroscopy to confirm 
that the native fold was present. A comparison of 
the H chemical shifts of the grafted peptides 
with the native peptide is shown in Figure 4. 
Only the amino acids that are common with 
kalata B1 are shown and the comparison 
indicates that the overall structures of the 
peptides are similar. The only H chemical shift 
differences larger than 0.2 ppm were found for 
Val29, which is the C-terminal neighbor to the 
grafted sequence, Cys1 which is bound to Val29 
and Cys15 which forms a disulfide with Cys1. 
The peptides kB1[HFRW;24-27] and 
kB1[HfRW;24-27] had additional peaks in the 
NMR spectra (data not shown) as a result of 
cis/trans isomerization at the Trp27/Pro28 
peptide bond. The major conformation, judging 
from the intensity of the peaks, was the cis-Pro 
conformation. The two conformers of 
kB1[HfRW;24-27] were distinguished by a 
strong NOE cross-peak between Hα-Hα protons 
of Trp27 and Pro28 (4.24 ppm; 3.33 ppm) in the 
major conformation and a weaker NOE cross-
peak between Hα-Hδ protons (5.01 ppm; 3.91 
ppm) in the minor conformation.  
 
Melanocortin assays 
The binding affinities of the four synthesized 
melanocortin analogs of kalata B1 to the 
melanocortin receptors 1 and 3-5 were 
determined by competition binding assays using 
radiolabeled NDP-α-MSH. Kalata B1 and α-
MSH were also evaluated as controls. The 
results are given in Table 2 and results from 
binding studies of kalata B1, kB1[GHFRWG;23-
28] and α-MSH at the MC4R are shown in 
Figure 3. KB1[GHFRWG;23-28] had a Ki of 29 
nM at the MC4R and was 107 or 314 times 
selective for the MC4R over the MC1R or 
MC5R respectively. The peptide was not able to 
bind to the MC3R. The Ki of α-MSH at the 
MC4R receptor was 39 nM. KB1[GHFRWG;23-
28] was also tested in a functional assay to 
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evaluate the potency at the MC4R. The EC50 of 
kB1[GHFRWG;23-28] was determined to be 
580 nM, while α-MSH had an EC50 of 3.7 nM 
(Table 2). 
 
Three-dimensional structure of 
kB1[GHFRWG;23-28] 
Given the potency and selectivity observed for 
kB1[GHFRWG;23-28], the three-dimensional 
structure was determined to provide insight into 
structure activity relationships. Structures were 
determined using torsion angle dynamics in the 
program CYANA and the 20 structures with the 
lowest target function chosen to represent the 
global fold. Energetic and geometric statistics 
are given in Table 3. Analysis of the structures 
with PROMOTIF [50] revealed that the major 
element of secondary structure is a -hairpin 
involving residues 16-18 and 21-23. A third 
strand comprising residues 3-4 is associated with 
the hairpin to form a triple-stranded -sheet as 
shown in Figure 5. In addition, residues 5-8 form 
a type I -turn, and residues 10-12 and 12-14 
form inverse -turns. Comparison of the 
structure of kB1[GHFRWG;23-28] with the 
native kalata B1 framework indicates that the 
overall fold is maintained. The cyclic cystine 
knot motif and -hairpin are the defining 
structural features of the cyclotides and both are 
present in kB1[GHFRWG;23-28], despite the 
sequence changes in loop 6. The introduction of 
non-native sequences into the CCK scaffold can 
sometimes lead to disordered loops [43,46]. 
However, for kB1[GHFRWG;23-28] the grafted 
loop 6 is as well defined as the other loops, with 
order parameters >0.93 for the  and  angles 
over the whole molecule.   
The grafted sequence has several large 
hydrophobic residues, including His, Phe and 
Trp and it was of interest to determine how their 
presence might influence the nature of the 
cyclotide surface. Analysis of the surface of 
kB1[GHFRWG;23-28] shows that a set of 
surface-exposed hydrophobic residues are 
punctuated by polar or charged residues. In 
addition, the arginine in loop 6 is highly solvent 
exposed. A similar distribution of surface 
residues is evident in kalata B1, with the 
exception of loop 6, as illustrated in Figure 6. 
 
Proteolytic stability 
To investigate the stability of the peptides kalata 
B1, kB1[GHFRWG;23-28] and α-MSH were 
incubated with chymotrypsin. As shown in 
Figure 7, more than 95% of kalata B1 remained 
intact for five hours. KB1[GHFRWG;23-28] 
was slightly less stable but around 80% of 
kB1[HfRW;24-27] was intact after five hours. 
After 24 hours, the amounts of intact peptide had 
not changed further, but this is probably due to 
auto-cleavage of chymotrypsin by this time. 
Compared to kalata B1, kB1[GHFRWG;23-28] 
has two additional potential chymotrypsin 
cleavage sites in the grafted sequence, so the 
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observed resistance to proteolysis is a significant 
finding. Finally, α-MSH completely degraded 
within ten minutes. 
 
Discussion 
In this study we used the kalata B1 cyclotide 
scaffold to design a novel agonist for the MC4R. 
This analogue (kB1[GHFRWG;23-28]) also 
showed selectivity over other MCRs tested, 
highlighting the potential of the CCK scaffold 
for targeting specific interactions implicated in 
regulation of appetite and energy homeostasis, 
and providing a possible lead molecule for the 
treatment of obesity. Interestingly, 
kB1[GHFRWG;23-28] showed higher affinity 
for the MC4R compared to the native agonist α-
MSH but was not as potent functionally. It 
appears likely that kB1[GHFRWG;23-28] has 
stronger binding to the active site than α-MSH 
but due to the placement of the pharmacophore 
within the kalata B1 scaffold and possible steric 
clashes with the receptor it is not able to induce 
a similar conformational change in the receptor, 
which is required for full activation of the cAMP 
cascade. Nevertheless, significant 
(submicromolar) activation of the cAMP 
response was observed. This successful example 
of grafting a function into a cyclotide adds to a 
growing body of evidence that the CCK 
framework can accommodate a diverse range of 
bioactivities. 
Four analogues of kalata B1 were 
synthesized using Boc chemistry and generally 
folded well using the oxidation conditions 
previously established for native kalata B1 
(Figure 2). All of the analogues retained the 
native fold based on analysis with NMR 
spectroscopy. Even though six out of the seven 
residues in loop 6 were replaced, the CCK holds 
the remaining loops in place and allows these 
changes in loop 6. These results confirm the 
plasticity of the cyclotide scaffold previously 
reported [42], and in particular the tolerance of 
loop 6 to changes. This tolerance is further 
demonstrated by observations that loop 6 can be 
truncated and opened to produce acyclic cystine 
knot derivatives that maintain the same global 
fold as kalata B1 [54]. In essence, the exposed 
loops of the CCK framework can be regarded as 
‘plug and play’ cassettes that can be substituted 
to introduce a desired biological activity. 
Interestingly, kB1[GHfRWG;23-28], the 
D-Phe25 analogue of kB1[GHFRWG;23-28] 
bound with lower affinity to the MCRs than the 
all-L graft. This was surprising, since D-Phe 
analogues of short linear peptides are known to 
have higher affinity for the MCRs compared to 
L-Phe analogues [20]. The locked conformation 
of the pharmacophore in loop 6 of kalata B1 
could change the presentation to the active site 
of the receptors and consequently be an 
explanation for this observation. There is clearly 
potential for further optimization of the bioactive 
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epitope and these studies are planned in our 
laboratory. 
The NMR spectra for kB1[HFRW;24-
27] and kB1[HfRW;24-27] revealed that two 
conformations were present. This 
conformational heterogeneity appears to be 
related to cis/trans isomerization around Pro28. 
The major conformation, based on inter-residue 
cross-peaks was the cis conformation. This was 
confirmed by a strong Hα-Hα cross-peak 
between Trp27 and Pro28. The cis-Pro 
conformation is consistent with what has 
previously been described for the Trp19–Pro20 
bond in kalata B1 [33,55]. The strong Hα-Hα 
cross peak between Trp19 and Pro20 was 
observed in all peptides, whereas a Hα-Hδ cross 
peak was observed for the Thr12-Pro13 bond. 
The cis-Pro20 bond causes a conceptual twist in 
the backbone, which defines the Möbius family 
of cyclotides [33]. The additional twist caused 
by the cis-Pro28 bond changes the topology of 
kB1[HFRW;24-27] and kB1[HfRW;24-27]. This 
could be part of the reason why they did not bind 
to the MCRs, since a twist in the backbone 
around the pharmacophore changes the 
presentation of the side chains at the active site 
of the receptors. Besides the conformational 
change, it is also possible that the side chains of 
Thr23 and Pro28 in kB1[HFRW;24-27] and 
kB1[HfRW;24-27] affect the binding of the 
pharmacophore to the active site of the MCRs 
negatively compared to Gly23 and Gly28 in 
kB1[GHFRWG;23-28] and 2, which due to their 
lack of side chain would interfere less with the 
active site. 
The intrinsic resistance of α-MSH to 
proteolytic degradation is very low but can be 
somewhat increased by engineering a single 
disulfide in the sequence [56]. Kalata B1 has 
been demonstrated to have significantly 
increased stability towards enzymatic 
degradation compared to non-cystine knotted 
analogues, linear cystine knotted peptides and 
non-cyclic peptides [38]. It was of interest to 
determine if the target grafting epitope would 
have enhanced resistance to proteolysis when 
incorporated into the cyclotide framework. 
Chymotrypsin cleavage assays for 
kB1[GHFRWG;23-28], kalata B1 and α-MSH 
confirmed this expectation. Whereas α-MSH 
was completely degraded within ten minutes 
under the conditions studied, kalata B1 was 95% 
intact after five hours and remained stable even 
after 24 hours, probably due to auto-cleavage of 
chymotrypsin. KB1[GHFRWG;23-28] was only 
slightly less stable than kalata B1, being 80% 
intact after five hours. This marginal loss of 
stability is surprising on one hand since the 
grafted sequence in loop 6 contains two potential 
chymotrypsin cleavage sites and hence the 
sequence is intrinsically susceptible to 
proteolysis. On the other hand, the results 
provide clear confirmation of the ability of the 
cyclotide framework to stabilize even a 
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‘susceptible’ epitope. The observation that 
kB1[GHFRWG;23-28] was more than 80% 
intact after extended incubation with 
chymotrypsin confirms the high stability towards 
enzymatic degradation of both kalata B1 and 
grafted analogues thereof.  
Cyclotides and other cystine knot micro-
proteins have been suggested to have the 
potential for oral delivery, partly because of their 
high stability [57,58]. This potential was 
recently demonstrated in the development of an 
analogue of kalata B1 that is orally active in a 
mouse model of inflammatory pain [44], 
suggesting that similar exciting results for the 
oral route of drug delivery might be achieved 
with other examples of kalata B1 grafting. The 
analogues of kalata B1 reported here represent a 
new group of selective melanocortin agonists. 
Because of their cyclotide framework they are 
more stable than previously reported linear and 
mono-cyclic melanocortin analogs, and with 
further optimization this group of peptides could 
provide new peptide-based leads with the 
potential to treat obesity. 
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Footnotes 
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Figure 1. a) The primary sequence of kalata B1. The disulfide bonds and circular backbone are 
indicated with lines, and the inter-cysteine-loops labeled below the sequence. Loop 6, in which the 
melanocortin sequences are grafted, is highlighted in blue. b) The four sequences grafted into loop 6. 
The lower case f refers to D-Phe. Non-native kalata B1 residues are highlighted in red. c) The 
structure of kalata B1 (PDB ID 1nb1), with disulfides indicated and loop 6 highlighted in blue [59]. 
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Figure 2. Chromatograms from the preparative HPLC purifications of the grafted peptides. The peaks 
corresponding to the correctly folded peptides are marked with an asterisk. 
 
Figure 3. MC4R binding assays for kB1[GHFRWG;23-28], kalata B1 and α-MSH. Each assay was 
performed in duplicate. Cell membranes expressing the MC4R were incubated with 125I-NDP-α-MSH 
and the synthesized peptides. The amount of radioactivity from bound 125I-NDP-α-MSH was counted 
and Ki values were calculated. Data points are average values from the assays and SEM values are 
indicated with error bars. 
 
Figure 4. The Hα chemical shifts of the four synthesized peptides and kalata B1. The numbers 
corresponding to cysteine residues are highlighted in bold. 
 
Figure 5. a) Overlay of the 20 minimum energy structures of kB1[GHFRWG;23-28]. b) Ribbon 
model of the NMR derived structure of kB1[GHFRWG;23-28]. PDB ID 2lur. c) Ribbon model of 
kalata B1. PDB ID 1nb1. 
 
Figure 6. Surface representation of kB1[GHFRWG;23-28] (left) and kalata B1 (right). The only 
major differences are observed in the grafted loop 6, i.e. residues 23-28. Hydrophobic residues are 
highlighted in green, positively charged in blue, negatively charged in red, cysteines in yellow and 
polar in cyan. The top views have similar orientation as the ribbon models in Figure 5. The residues 
F25, R26 and W27 in kB1[GHFRWG;23-28] are part of the melanocortin pharmacophore grafted into 
loop 6 of kalata B1. 
 
Figure 7. Enzymatic stability of kalata B1, kB1[GHFRWG;23-28] and α-MSH towards chymotrypsin 
cleavage. The peptides were incubated with chymotrypsin for five hours at 37°C. The enzyme to 
peptide ratio was 1:5 w/w (1:10 w/w for α-MSH to have equal molar ratios). The insert shows the 
degradation of α-MSH the first ten minutes of incubation. 
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Table 1. Nomenclature, sequences and disulfide pattern of grafted cyclotides with their corresponding 
masses. The sequence of α-MSH is shown below. 
Peptide Primary structure Calculated 
mass (Da)a 
Observed 
mass (Da)a 
 
kalata B1  
kB1[GHFRWG;23-28] 
kB1[GHfRWG;23-28]  
kB1[HFRW;24-27] 
kB1[HfRW;24-27] 
 
α-MSH 
 
         CGETCVGGTCNTPGCTCSWPVCTRNGLPV 
         CGETCVGGTCNTPGCTCSWPVCGHFRWGV  
         CGETCVGGTCNTPGCTCSWPVCGHfRWGV 
         CGETCVGGTCNTPGCTCSWPVCTHFRWPV 
         CGETCVGGTCNTPGCTCSWPVCTHfRWPV 
         1         5           10         15          20         25 
   Ac-SYSMEHFRWGKPV 
 
2890.1 
2992.1 
2992.1 
3076.2 
3076.2 
 
2890.0 
2992.0 
2991.9 
3076.1 
3076.1 
 a monoisotopic mass 
 
Table 2. Binding affinity of grafted cyclotides for melanocortin receptors 1 and 3-5 and functional 
activity at MCR4 of the most potent binder.   
Peptide hMC1R 
pKi 
(Ki/[nM]) 
hMC3R 
pKi 
(Ki/[nM]) 
hMC4R 
pKi 
(Ki/[nM]) 
hMC4R cAMP 
pEC50 
(EC50/[nM]) 
hMC5R 
pKi 
(Ki/[nM]) 
kalata B1 Na. 
 
Na. Na.  Na. 
kB1[GHFRWG;23-28] 5.50 ± 0.09  
(3,100) 
Na.  7.53 ± 0.28 
(29) 
6.24 ± 0.08 
(580) 
5.04 ± 0.14 
(9,100) 
kB1[GHfRWG;23-28] 6.37 ± 0.06 
(420) 
5.11 ± 0.03 
(7,700)  
6.59 ± 0.15 
(250) 
 5.30 ± 0.04 
(5,000) 
kB1[HFRW;24-27] Na. 
 
Na. Na.  Na. 
kB1[HfRW;24-27] Na. 
 
Na. Na.  Na. 
α-MSH 9.16 ± 0.05  
(0.69) 
7.51 ± 0.04  
(31) 
7.41 ± 0.26 
(39) 
8.44 ± 0.26 
(3.7) 
6.75 ± 0.16 
(180) 
Na: no activity (i.e. Ki > 10,000 nM). Data represents an average pKi of three replicates ± SEM. Ki 
value (in brackets) is calculated from the average pKi value. Potency at the MC4R was determined 
only for kB1[GHFRWG;23-28]. 
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Table 3. NMR and refinement statistics for the structure of kB1[GHFRWG;23-28]. 
NMR distance and dihedral constraints  
Distance constraints  
   Total NOE 291 
      Short-range (|i-j|<1) 202 
      Medium-range (1<|i-j|<5) 42 
      Long-range (|i-j|5) 47 
Dihedral angle restraints  
    12 
Structure statistics  
CYANA target function 1.02±0.07 
Violations (mean and s.d.)  
   Distance constraints, RMSD (Å) 0.01±0.002 
   Dihedral angle constraints, RMSD (°) 1.45±0.12 
   Max. distance constraint violation (Å)  0.26 
   Max. dihedral angle violation (°) 1.01 
Average pairwise r.m.s. deviation*  (Å)  
   Backbone 0.41±0.11 
   Heavy 0.84±0.18 
Ramachandran statistics  
   Residues is most favored regions 49.5% 
   Residues in additionally allowed regions 50.5% 
*Pairwise RMSD was calculated from the 20 structures with the lowest target function. 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
 
 
 
 
 
 
